<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.1 20151215//EN" "JATS-archivearticle1.dtd"> 
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="review-article"><?properties open_access?><?DTDIdentifier.IdentifierValue -//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.1 20151215//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName JATS-journalpublishing1.dtd?><?SourceDTD.Version 1.1?><?ConverterInfo.XSLTName jp2nlmx2.xsl?><?ConverterInfo.Version 1?><front><journal-meta><journal-id journal-id-type="nlm-ta">Int J Mol Sci</journal-id><journal-id journal-id-type="iso-abbrev">Int J Mol Sci</journal-id><journal-id journal-id-type="publisher-id">ijms</journal-id><journal-title-group><journal-title>International Journal of Molecular Sciences</journal-title></journal-title-group><issn pub-type="epub">1422-0067</issn><publisher><publisher-name>MDPI</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">5713374</article-id><article-id pub-id-type="doi">10.3390/ijms18112406</article-id><article-id pub-id-type="publisher-id">ijms-18-02406</article-id><article-categories><subj-group subj-group-type="heading"><subject>Review</subject></subj-group></article-categories><title-group><article-title>Antidepressants and Mood Stabilizers: Novel Research Avenues and Clinical Insights for Bipolar Depression</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Shim</surname><given-names>In Hee</given-names></name><xref ref-type="aff" rid="af1-ijms-18-02406">1</xref></contrib><contrib contrib-type="author"><name><surname>Woo</surname><given-names>Young Sup</given-names></name><xref ref-type="aff" rid="af2-ijms-18-02406">2</xref></contrib><contrib contrib-type="author"><name><surname>Kim</surname><given-names>Moon-Doo</given-names></name><xref ref-type="aff" rid="af3-ijms-18-02406">3</xref></contrib><contrib contrib-type="author"><name><surname>Bahk</surname><given-names>Won-Myong</given-names></name><xref ref-type="aff" rid="af2-ijms-18-02406">2</xref><xref rid="c1-ijms-18-02406" ref-type="corresp">*</xref></contrib></contrib-group><aff id="af1-ijms-18-02406"><label>1</label>Department of Psychiatry, Cancer Center, Dongnam Institute of Radiological &#x00026; Medical Sciences, Busan 46033, Korea; <email>ihshim1224@gmail.com</email></aff><aff id="af2-ijms-18-02406"><label>2</label>Department of Psychiatry, College of Medicine, The Catholic University of Korea, Seoul 07345, Korea; <email>youngwoo@catholic.ac.kr</email></aff><aff id="af3-ijms-18-02406"><label>3</label>Department of Psychiatry, School of Medicine, Jeju National University, Jeju 63241, Korea; <email>mdkim66@jejunu.ac.kr</email></aff><author-notes><corresp id="c1-ijms-18-02406"><label>*</label>Correspondence: <email>wmbahk@catholic.ac.kr</email>; Tel.: +82-2-3779-1250</corresp></author-notes><pub-date pub-type="epub"><day>13</day><month>11</month><year>2017</year></pub-date><pub-date pub-type="collection"><month>11</month><year>2017</year></pub-date><volume>18</volume><issue>11</issue><elocation-id>2406</elocation-id><history><date date-type="received"><day>29</day><month>9</month><year>2017</year></date><date date-type="accepted"><day>09</day><month>11</month><year>2017</year></date></history><permissions><copyright-statement>&#x000a9; 2017 by the authors.</copyright-statement><copyright-year>2017</copyright-year><license license-type="open-access"><license-p>Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>).</license-p></license></permissions><abstract><p>The concept of the bipolar-spectrum and of mixed features being a bridge between major depressive disorders and bipolar disorders (BDs) has become increasingly important in mood-disorder diagnoses. Under these circumstances, antidepressants (ADs) and mood stabilizers (MSs) should be used with caution in the treatment of major depressive episodes (MDEs) and to obtain long-term stability in BDs. Before treating MDEs, screening tools, specific symptom evaluation and medical history should be used to distinguish between bipolarity and mixed features in patients for whom AD monotherapy may present a risk. In these patients, a combination of ADs plus MSs or atypical antipsychotics is recommended, rather than AD monotherapy. Studies evaluating MSs for bipolar depression suggest that lamotrigine is the most reliable treatment and lithium has modest effects; there is a lack of clear evidence regarding the efficacy of valproate and carbamazepine. Recently, significant progress has been made with respect to the pathophysiology of mood disorders and the application of potential biomarkers. There is an opportunity to study novel drug mechanisms through the rediscovery of fast-acting drugs such as ketamine. It is anticipated that future research developments will involve the discovery of potential targets for new drugs and their application to personalized treatments.</p></abstract><kwd-group><kwd>antidepressant</kwd><kwd>mood-stabilizer</kwd><kwd>lithium</kwd><kwd>depression</kwd><kwd>mixed features</kwd><kwd>major depressive episode</kwd><kwd>bipolar disorder</kwd></kwd-group></article-meta></front><body><sec id="sec1-ijms-18-02406"><title>1. Introduction</title><p>Recent preliminary evidence suggests a potential trans-nosological effect of selected atypical antipsychotics (AAPs) beyond only psychotic disorders. Treatment with antipsychotics is an effective augmentation option for major depressive disorders (MDDs), bipolar mania and depression. For cases of non-psychotic depression with no response to the initial treatment strategy, some guidelines suggest augmentation of treatment with an AAP such as aripiprazole or quetiapine [<xref rid="B1-ijms-18-02406" ref-type="bibr">1</xref>,<xref rid="B2-ijms-18-02406" ref-type="bibr">2</xref>,<xref rid="B3-ijms-18-02406" ref-type="bibr">3</xref>]. In the past, the preferred initial treatment strategy for mania, regardless of type, was MSs plus AAPs; however, recently, AAP monotherapy has been considered the most effective first-line treatment [<xref rid="B4-ijms-18-02406" ref-type="bibr">4</xref>,<xref rid="B5-ijms-18-02406" ref-type="bibr">5</xref>,<xref rid="B6-ijms-18-02406" ref-type="bibr">6</xref>]. AAP monotherapy is recommended for mildly severe bipolar depression, while AAPs combined with mood stabilizers (MSs) or antidepressants (ADs) are recommended for moderate to severe depression [<xref rid="B4-ijms-18-02406" ref-type="bibr">4</xref>,<xref rid="B7-ijms-18-02406" ref-type="bibr">7</xref>].</p><p>Despite the increasing use of AAPs, MSs continue to play an important role in the management of bipolar mania and depression. Most mood disorders are characterized by the onset of a major depressive episode (MDE), and AD monotherapy is typically the first-line treatment. However, for bipolar disorders (BDs), AD monotherapy is very rarely recommended despite the high prevalence of depressive episodes. The risk-benefit profile of AD monotherapy for BDs remains controversial. Most guidelines suggest ADs as an adjuvant therapy with MSs [<xref rid="B8-ijms-18-02406" ref-type="bibr">8</xref>], as a short-term rather than long-term treatment [<xref rid="B9-ijms-18-02406" ref-type="bibr">9</xref>]. The proper use of MSs with ADs is very important during the acute phase of MDEs and the maintenance phase of BDs.</p><p>This review provides an overview of standard AD and MS treatments for both the acute phase of MDEs and long-term stabilization of BDs.</p></sec><sec id="sec2-ijms-18-02406"><title>2. Comparison of MDEs in MDDs and BDs</title><p>For MDEs, it is difficult to distinguish between MDDs and BDs based on the clinical symptoms alone. The Diagnostic and Statistical Manual of Mental Disorder (DSM) and the International Classification of Disease diagnostic criteria for the two disorders are very similar. In research and in clinical practice, assessments of symptom severity and changes in symptoms are conducted using the same methods (e.g., the Hamilton Depression Rating Scale (HAMD) or the Montgomery-Asberg Depression Rating Scale (MADRS)). Because most patients with BDs present with the onset of a MDE, one-half to two-thirds of patients are initially misdiagnosed [<xref rid="B10-ijms-18-02406" ref-type="bibr">10</xref>,<xref rid="B11-ijms-18-02406" ref-type="bibr">11</xref>]. More than one-third remain misdiagnosed for 5&#x02013;10 years or more [<xref rid="B12-ijms-18-02406" ref-type="bibr">12</xref>,<xref rid="B13-ijms-18-02406" ref-type="bibr">13</xref>].</p><p>Although there are many similarities between unipolar and bipolar depression, there are a number of significant differences. Patients with MDDs typically report more somatization and affective symptoms such as anxiety, anger, and agitation, and less anhedonia [<xref rid="B14-ijms-18-02406" ref-type="bibr">14</xref>]. Contrarily, patients with bipolar depression tend to experience more atypical symptoms such as hypersomnia, hyperphagia, and leaden paralysis, as well as psychomotor retardation, psychotic features, pathological guilt, and lability of mood, although there are no pathognomonic biomarkers or clinical characteristics [<xref rid="B15-ijms-18-02406" ref-type="bibr">15</xref>]. Regarding the long-term course of these illnesses, patients with bipolar depression are more likely to have an earlier age of onset [<xref rid="B16-ijms-18-02406" ref-type="bibr">16</xref>], more prior episodes of depression [<xref rid="B17-ijms-18-02406" ref-type="bibr">17</xref>], shorter depressive episodes [<xref rid="B18-ijms-18-02406" ref-type="bibr">18</xref>], a family history of BDs [<xref rid="B19-ijms-18-02406" ref-type="bibr">19</xref>], comorbid substance use disorder [<xref rid="B20-ijms-18-02406" ref-type="bibr">20</xref>], and a higher risk of postpartum depression [<xref rid="B21-ijms-18-02406" ref-type="bibr">21</xref>].</p><p>In the past, most treatment strategies were based on the type of mood disorder and episodic polarity, which were differentiated early in treatment. However, recent diagnostic and treatment approaches have focused on transdiagnostic psychopathology, spectrum, and dimensional classifications. The process reflecting the tendency of these changes is shown in <xref ref-type="fig" rid="ijms-18-02406-f001">Figure 1</xref>. First, a syndromal concept, such as bipolar-spectrum disorder including bipolar I, II, and not otherwise specified (NOS) and mixed features presenting subthreshold hypo (manic) symptoms (although DSM-5 criteria for bipolar-spectrum disorder or mixed features specifier no longer met) should be checked at the beginning of MDE treatment. Careful assessment of bipolar symptoms using screening instruments (e.g., the hypomania checklist (HCL-32)), mood depression questionnaires (MDQs), screening assessment of depression-polarity (SAD-P)) or mental status examinations, patient history and clinical course, and family history is crucial to treatment decisions [<xref rid="B22-ijms-18-02406" ref-type="bibr">22</xref>]. In addition, symptomatic (HAMD, MADRS, Young Mania Rating Scale (YMRS)) and functional (premorbid occupational and daily life functioning status) aspects must be evaluated [<xref rid="B23-ijms-18-02406" ref-type="bibr">23</xref>].</p></sec><sec id="sec3-ijms-18-02406"><title>3. ADs</title><sec id="sec3dot1-ijms-18-02406"><title>3.1. AD Monotherapy</title><p>According to most clinical guidelines, AD monotherapy is recommended as the first-line treatment for non-psychotic MDEs without hypomanic or manic symptoms [<xref rid="B1-ijms-18-02406" ref-type="bibr">1</xref>,<xref rid="B3-ijms-18-02406" ref-type="bibr">3</xref>,<xref rid="B24-ijms-18-02406" ref-type="bibr">24</xref>,<xref rid="B25-ijms-18-02406" ref-type="bibr">25</xref>]. Newer AD agents, such as selective serotonin reuptake inhibitors (SSRIs) and serotonin-norepinephrine reuptake inhibitors (SNRIs) are preferred over older treatments [<xref rid="B4-ijms-18-02406" ref-type="bibr">4</xref>]. These early stage MDEs usually require consideration of MDDs clinically first and follow the MDD treatment algorithms.</p><p>Studies evaluating prescription patterns indicate that ADs are prescribed for more than 50% of patients with bipolar depression [<xref rid="B26-ijms-18-02406" ref-type="bibr">26</xref>,<xref rid="B27-ijms-18-02406" ref-type="bibr">27</xref>]. Several randomized trials have found AD monotherapy to be an effective and safe treatment for bipolar depression; however, most of the studies were limited by small sample sizes, short durations, or lack of a control group [<xref rid="B28-ijms-18-02406" ref-type="bibr">28</xref>,<xref rid="B29-ijms-18-02406" ref-type="bibr">29</xref>,<xref rid="B30-ijms-18-02406" ref-type="bibr">30</xref>]. The EMBOLDEN II trial found that paroxetine significantly improved HAMD scores, particularly in patients who had a good response and who had not used ADs previously [<xref rid="B31-ijms-18-02406" ref-type="bibr">31</xref>].</p><p>AD monotherapy during the acute phase of a MDE must be administered carefully, as the response to ADs differs between MDD and BD patients. When ADs are used to treat bipolar depression, adverse effects may include mood switches, irritability, and agitation, even if not to the extent of mood switching; they can accelerate episode frequency or induce rapid cycling, and can increase the risk of suicide behaviors [<xref rid="B8-ijms-18-02406" ref-type="bibr">8</xref>]. There is a limited role for ADs as an adjunctive therapy to MSs or AAPs for treating the acute phase of bipolar depression.</p></sec><sec id="sec3dot2-ijms-18-02406"><title>3.2. Efficacy and Safety of ADs</title><p>A meta-analysis of the efficacy and safety of ADs for bipolar depression revealed inconsistent results. One study indicated statistically significant overall efficacy of ADs in acute bipolar depression, while another reported that there was only a trend for higher response rates in patients treated with ADs [<xref rid="B32-ijms-18-02406" ref-type="bibr">32</xref>,<xref rid="B33-ijms-18-02406" ref-type="bibr">33</xref>].</p><p><xref ref-type="table" rid="ijms-18-02406-t001">Table 1</xref> lists randomized controlled trials (RCTs) that evaluated ADs as a treatment for acute depression in BDs. Fluoxetine plus olanzapine (OFC) was the most effective treatment, while results for other ADs varied. Treatment with OFC was significantly more effective than olanzapine alone or the placebo in treatment of bipolar I depression, without increasing the risk of manic symptoms [<xref rid="B34-ijms-18-02406" ref-type="bibr">34</xref>]. In another study, OFC was found more effective than lamotrigine for the treatment of bipolar I depression, although some increases in metabolic factors were observed [<xref rid="B35-ijms-18-02406" ref-type="bibr">35</xref>]. Contrarily, paroxetine, bupropion, and agomelatine adjunctive therapies did not differ from the placebo or MS treatments [<xref rid="B31-ijms-18-02406" ref-type="bibr">31</xref>,<xref rid="B36-ijms-18-02406" ref-type="bibr">36</xref>,<xref rid="B37-ijms-18-02406" ref-type="bibr">37</xref>]. </p><p>Interestingly, the bupropion group showed a significantly lower risk of mood switch rates compared to other ADs (sertraline, venlafaxine, and desipramine); however, compared to other ADs, venlafaxine must be used cautiously [<xref rid="B47-ijms-18-02406" ref-type="bibr">47</xref>,<xref rid="B49-ijms-18-02406" ref-type="bibr">49</xref>,<xref rid="B56-ijms-18-02406" ref-type="bibr">56</xref>]. Therefore, adjunctive treatments with SNRIs, such as venlafaxine or tricyclic antidepressants (TCAs), should be considered only after other ADs (e.g., bupropion, SSRIs) have been administered, and must be closely monitored due to an increased risk of mood switching and destabilization [<xref rid="B8-ijms-18-02406" ref-type="bibr">8</xref>,<xref rid="B33-ijms-18-02406" ref-type="bibr">33</xref>,<xref rid="B57-ijms-18-02406" ref-type="bibr">57</xref>].</p><p>There is a lack of data regarding rapid cycling of ADs in RCTs. As part of the Systematic Treatment Enhancement Program for Bipolar Disorder (STEP-BD) study, AD continuation with rapid cycling was associated with worsened maintenance outcomes, especially for depressive morbidity, compared to the AD discontinuation group [<xref rid="B58-ijms-18-02406" ref-type="bibr">58</xref>]. However, rapid cycling status may not be associated with a diminished response or greater depressive relapse during venlafaxine treatment relative to lithium monotherapy in bipolar II subjects [<xref rid="B59-ijms-18-02406" ref-type="bibr">59</xref>]. Additional research is required in this area.</p><p>There is still a lack of evidence that the use of ADs for depression in BDs increases suicidal ideation and suicidal behavior, AD monotherapy of bipolar depression may entrain a course characterized by higher proneness to mood switches and suicidal behavior [<xref rid="B60-ijms-18-02406" ref-type="bibr">60</xref>,<xref rid="B61-ijms-18-02406" ref-type="bibr">61</xref>]. However, in some studies, patients with bipolar I and II disorders showed either no evidence of, or a significant reduction in, the risk of suicidal behavior during periods of AD exposure [<xref rid="B62-ijms-18-02406" ref-type="bibr">62</xref>,<xref rid="B63-ijms-18-02406" ref-type="bibr">63</xref>,<xref rid="B64-ijms-18-02406" ref-type="bibr">64</xref>]. It should be noted that some suicidal subjects had unconfirmed mixed features [<xref rid="B61-ijms-18-02406" ref-type="bibr">61</xref>,<xref rid="B65-ijms-18-02406" ref-type="bibr">65</xref>,<xref rid="B66-ijms-18-02406" ref-type="bibr">66</xref>].</p></sec><sec id="sec3dot3-ijms-18-02406"><title>3.3. Clinical Application of ADs</title><p>In clinical practice, most guidelines recommend combination therapy with MSs or AAPs, particularly lamotrigine and AAPs, rather than AD monotherapy for bipolar depression [<xref rid="B4-ijms-18-02406" ref-type="bibr">4</xref>,<xref rid="B5-ijms-18-02406" ref-type="bibr">5</xref>,<xref rid="B7-ijms-18-02406" ref-type="bibr">7</xref>,<xref rid="B67-ijms-18-02406" ref-type="bibr">67</xref>,<xref rid="B68-ijms-18-02406" ref-type="bibr">68</xref>]. For mild to moderately severe cases, adjunctive AD therapy is often recommended as the second-line intervention, using SSRIs or bupropion combined with MSs or AAPs, particularly OFC. For moderate to severe cases, AD combination therapies are considered the first-line intervention.</p><p>Currently, there are no set guidelines for the dosage of ADs for bipolar depression. Tada et al. suggested that dose increments of adjunctive ADs might need to be considered for those receiving low doses who remain unresponsive [<xref rid="B69-ijms-18-02406" ref-type="bibr">69</xref>]. Although there is a lack of evidence regarding the relationship between AD dose and mood switching in bipolar depression, use of adjunctive ADs may be associated with increased severity of manic symptoms in the STEP-BD [<xref rid="B70-ijms-18-02406" ref-type="bibr">70</xref>].</p></sec><sec id="sec3dot4-ijms-18-02406"><title>3.4. ADs for Maintenance </title><p>Clinically, long-term AD use for depression in BD patients is very common. However, their role in preventing depressive or manic episode relapse is doubtful. There seems to be a prophylactic effect on depressive episodes. In a RCT of long-term fluoxetine versus lithium monotherapy for bipolar II disorder, fluoxetine monotherapy provided superior relapse prevention compared to lithium monotherapy as a maintenance treatment, although the results for fluoxetine and the placebo were comparable [<xref rid="B71-ijms-18-02406" ref-type="bibr">71</xref>]. In a STEP-BD study of ADs&#x02019; long-term effectiveness and safety, AD continuation with MSs trended toward less severe depressive symptoms (difference in DSM-IV depression criteria = &#x02212;1.84, 95% CI &#x02212;0.08&#x02013;3.77) and mildly delayed depressive episode relapse, without increased manic symptoms (mean difference in DSM-IV mania criteria = +0.29, 95% CI &#x02212;0.73&#x02013;1.20), although a rapid cycling course predicted three times more depressive episodes with AD continuation (rapid cycling = 1.29, non-rapid cycling = 0.42 episodes/year, <italic>p</italic> = 0.04) [<xref rid="B72-ijms-18-02406" ref-type="bibr">72</xref>].</p><p>However, in a meta-analysis of seven RCTs (350 bipolar depression patients), long-term treatment with MSs in combination with ADs yielded neither major protection from depression (RR = 0.84, 95% CI 0.56&#x02013;1.27) nor a substantial increase in the risk of mania (RR = 1.37, 95% CI 0.81&#x02013;2.33) [<xref rid="B9-ijms-18-02406" ref-type="bibr">9</xref>]. In a study of venlafaxine continuation, there were no differences in relapse rates between venlafaxine and lithium (7.5% vs. 26.7%, <italic>p</italic> = 0.079), relapse hazard (<italic>p</italic> = 0.073), or time to relapse (<italic>p</italic> = 0.090), possibly due to the small sample size and lack of a placebo [<xref rid="B29-ijms-18-02406" ref-type="bibr">29</xref>].</p><p>In conclusion, the efficacy of AD monotherapy in maintenance and in preventing recurrence are inconclusive. However, long-term AD use with anti-manic drugs in BDs may not increase the risk of relapse of mood disorder.</p></sec></sec><sec id="sec4-ijms-18-02406"><title>4. MSs</title><sec id="sec4dot1-ijms-18-02406"><title>4.1. Lithium</title><p>In the clinical literature on the acute depressive phase of BDs, eight of nine controlled comparisons found lithium superior to the placebo in depressed bipolar patients [<xref rid="B73-ijms-18-02406" ref-type="bibr">73</xref>]. For prophylactic treatment, the usefulness of lithium against bipolar depression was confirmed together with its specific effectiveness for suicide prevention [<xref rid="B74-ijms-18-02406" ref-type="bibr">74</xref>]. These anti-suicidal effects are possibly due to reducing mood disorder relapse, but additional mechanisms must be considered since there is some evidence that lithium decreases aggression and, possibly, impulsivity [<xref rid="B75-ijms-18-02406" ref-type="bibr">75</xref>]. However, some studies indicate that lithium may be less effective for depression than lamotrigine; lamotrigine may provide a spectrum of efficacy complementary to that of lithium [<xref rid="B76-ijms-18-02406" ref-type="bibr">76</xref>,<xref rid="B77-ijms-18-02406" ref-type="bibr">77</xref>].</p><p><xref ref-type="table" rid="ijms-18-02406-t001">Table 1</xref> shows that AD adjunctive therapy in addition to lithium may be beneficial. This is particularly observed in patients who cannot tolerate high serum lithium levels or those who have symptoms that are refractory to the AD effects of lithium [<xref rid="B44-ijms-18-02406" ref-type="bibr">44</xref>]. Among patients with delayed onset of therapeutic response and a high number of non-responders to ADs, there is firm evidence for lithium as an effective augmentation strategy, but only modest evidence that lithium accelerates the response to ADs in patients with depression [<xref rid="B78-ijms-18-02406" ref-type="bibr">78</xref>].</p><p>From the viewpoint that the concept of disease gradually expands into the bipolar-spectrum, longitudinal follow-up found a positive response to lithium augmentation in treatment-resistant MDE-related bipolar-spectrum disorder [<xref rid="B79-ijms-18-02406" ref-type="bibr">79</xref>]. This maintenance treatment, lithium monotherapy, was associated with a significantly reduced risk of both manic/mixed and depressed relapse [<xref rid="B74-ijms-18-02406" ref-type="bibr">74</xref>]. Moreover, quetiapine combination significantly reduced the risk of relapse of manic/mixed and depressive episodes in bipolar illness compared to the placebo. The risk of early recurrence of BDs, especially of mania, was found to increase following discontinuation of lithium use and may exceed that predicted in the course of the untreated disorder [<xref rid="B80-ijms-18-02406" ref-type="bibr">80</xref>].</p><p>Lithium is an essential form of treatment but must not be applied monotherapeutically for bipolar depression, particularly in the treatment of severe bipolar depression [<xref rid="B81-ijms-18-02406" ref-type="bibr">81</xref>]. As a combination treatment, lithium effectively prevents relapse and is particularly useful in patients with a high risk of suicide.</p></sec><sec id="sec4dot2-ijms-18-02406"><title>4.2. Lamotrigine</title><p>There have been several long-term studies of the effects of lamotrigine in the treatment of bipolar depression. Two placebo-controlled 18-month trials of lamotrigine indicated that it was effective against depression and mania, with more robust activity against depression [<xref rid="B77-ijms-18-02406" ref-type="bibr">77</xref>]. In a long-term study involving 124 patients with bipolar depression receiving lithium, addition of lamotrigine was significantly more effective than the placebo during the acute phase, and continued to be beneficial compared to the placebo during the maintenance phase [<xref rid="B82-ijms-18-02406" ref-type="bibr">82</xref>]. However, the effects of lamotrigine on the acute phase of bipolar depression are diverse and need to be studied further. In a naturalistic, open-label study of patients with bipolar II disorder, treatment of acute depression with lamotrigine or lithium showed comparable response and remission rates [<xref rid="B83-ijms-18-02406" ref-type="bibr">83</xref>]. Another RCT did not demonstrate efficacy of lamotrigine monotherapy as an acute treatment, although it was well tolerated [<xref rid="B84-ijms-18-02406" ref-type="bibr">84</xref>]. A RCT of the acute phase, comparing OFC to lamotrigine, showed that OFC-treated patients showed significant improvement compared to lamotrigine-treated patients in Clinical Global Impression&#x02014;Improvement (CGI-I) response and time to response, although the OFC treatment had undesirable side effects such as greater weight gain and some elevated metabolic factors compared to lamotrigine [<xref rid="B35-ijms-18-02406" ref-type="bibr">35</xref>]. Most guidelines recommend lamotrigine as the first-line treatment for mild to moderate bipolar depression [<xref rid="B4-ijms-18-02406" ref-type="bibr">4</xref>,<xref rid="B5-ijms-18-02406" ref-type="bibr">5</xref>,<xref rid="B7-ijms-18-02406" ref-type="bibr">7</xref>,<xref rid="B67-ijms-18-02406" ref-type="bibr">67</xref>,<xref rid="B68-ijms-18-02406" ref-type="bibr">68</xref>,<xref rid="B85-ijms-18-02406" ref-type="bibr">85</xref>]. Additionally, lamotrigine monotherapy or combined with lithium or AAPs is generally recommended.</p><p>For maintenance treatment, it has been reported that lamotrigine is effective in the prevention of depression, particularly the combination of lithium and lamotrigine [<xref rid="B86-ijms-18-02406" ref-type="bibr">86</xref>]. However, the overall pool effect was only modest, although the advantage over the placebo was larger in more severely depressed patients [<xref rid="B87-ijms-18-02406" ref-type="bibr">87</xref>].</p></sec><sec id="sec4dot3-ijms-18-02406"><title>4.3. Valproate/Carbamazepine</title><p>There have been several meta-studies related to treatment of the acute phase of bipolar depression with valproate and carbamazepine. One study on valproate showed that patients&#x02019; responses to, and remission with, valproate were significantly greater than with the placebo [<xref rid="B88-ijms-18-02406" ref-type="bibr">88</xref>]. According to another study, valproate and carbamazepine also produced favorable response rates compared to the placebo group, and the number needed to treat (NNT) was also low (valproate 4.4 and carbamazepine 3.4) [<xref rid="B89-ijms-18-02406" ref-type="bibr">89</xref>]. However, because the sample size of both studies was small (<italic>N</italic> = 140 and <italic>N</italic> = 142, respectively), more research is needed to make a definitive conclusion.</p><p>For maintenance treatment, some research suggests that valproate may prevent depressive episodes. Valproate and carbamazepine may be effective for bipolar depression, leading to decreased worsening of depressive symptoms and a reduced probability of depressive relapse [<xref rid="B74-ijms-18-02406" ref-type="bibr">74</xref>,<xref rid="B90-ijms-18-02406" ref-type="bibr">90</xref>]. A pilot study reported that a combination of lithium and valproate significantly reduced the chances of relapse or recurrence, although it was more likely to cause moderate to severe adverse side effects [<xref rid="B91-ijms-18-02406" ref-type="bibr">91</xref>]. A small RCT of carbamazepine concluded that it was as effective as lithium in the prophylaxis of bipolar affective disorder [<xref rid="B92-ijms-18-02406" ref-type="bibr">92</xref>]. However, some studies have shown that the prophylactic effect of carbamazepine is relatively low compared to other MSs or lithium, and that it may be better for broader spectrum disorders, such as bipolar II or bipolar not otherwise specified rather than lithium [<xref rid="B93-ijms-18-02406" ref-type="bibr">93</xref>,<xref rid="B94-ijms-18-02406" ref-type="bibr">94</xref>,<xref rid="B95-ijms-18-02406" ref-type="bibr">95</xref>,<xref rid="B96-ijms-18-02406" ref-type="bibr">96</xref>]. Additionally, lithium combination treatment, rather than carbamazepine monotherapy, has been shown to help prevent new episodes of relapse [<xref rid="B97-ijms-18-02406" ref-type="bibr">97</xref>].</p><p>In conclusion, there is little evidence for the efficacy of valproate or carbamazepine for acute bipolar depression, even though they are the most frequently prescribed MSs for BDs. To date, valproate and carbamazepine have been found to be less effective during acute-phase treatment of bipolar depression, maintenance treatment, and for depression relapse prevention compared to other MSs and lithium [<xref rid="B98-ijms-18-02406" ref-type="bibr">98</xref>].</p></sec></sec><sec id="sec5-ijms-18-02406"><title>5. Novel Research Avenues</title><p>To date, there are no significant biomarkers for mood disorders. The role of clinical evaluation in distinguishing between MDDs and BDs is very important. As shown in the differential diagnosis process in <xref ref-type="fig" rid="ijms-18-02406-f001">Figure 1</xref>, the history of hypomanic symptoms and long-term follow-up are the most obvious ways to distinguish bipolarity. Thus, most patients with MDEs undergo early AD monotherapy. In the process of clinical examination and observation of pharmacological responses, if bipolarity or mixed features are suspected, or if there is a partial or no response to early AD monotherapy, the classes of ADs are appropriately modified and combined with lithium and MSs or AAPs. However, the trial and error process of psychiatric treatment can worsen symptoms such as mood switching and rapid cycling, and lead to suicidal behavior. Therefore, it is necessary to develop biomarkers that can distinguish between mood disorders biologically before initiating treatment. This requires an understanding of the pathophysiology associated with MDDs and BDs.</p><p>Recent findings suggest that molecular biology, genetic/epigenetic markers, neuroimaging, and inflammatory markers, oxidative stress, and mitochondrial dysfunction may be candidates to provide differential diagnosis and indicate drug responsiveness. The relationship of single nucleotide polymorphism (SNP) to AD responsiveness has been determined. Recently, gene-expression analysis has examined the involvement of miRNA in predisposing biological processes associated with antidepressant responses. miRNA in peripheral blood leukocytes may be a biomarker for MDDs, suicide, and cognitive function [<xref rid="B99-ijms-18-02406" ref-type="bibr">99</xref>,<xref rid="B100-ijms-18-02406" ref-type="bibr">100</xref>,<xref rid="B101-ijms-18-02406" ref-type="bibr">101</xref>]. If genetic studies can predict a patient&#x02019;s drug responsiveness, then the most appropriate drug can be selected as personalized medicine. In the case of mental illness, there are too many complex considerations involving social and psychological factors, and research on genetic pathophysiology has been lacking. However, in the case of other diseases, biological studies on pathophysiology and drug responses have been actively conducted and are already in the process of providing personalized drug treatments. Mood disorders, particularly MDEs, which are among the most common diseases in psychiatry will follow this trend.</p><p>For example, differences in fluoxetine response may be due to the influence of certain genes involved in fluoxetine transportation. Genetic variation in transport and remission, recovery, suicide risk, and other factors such as stress, family support, and other genetic factors are likely to be involved in MDD outcomes [<xref rid="B102-ijms-18-02406" ref-type="bibr">102</xref>]. In addition, if venlafaxine is more effective in Val/Val patients than Met/Met carriers, the Catechol-O-methytransferase (COMT) Val/Met genetic polymorphism can be recommended as a biomarker for the prediction of venlafaxine efficacy in patients treated in psychiatric settings [<xref rid="B103-ijms-18-02406" ref-type="bibr">103</xref>]. For MSs, evidence increasingly suggests that genetic factors play a strong role in the variation of response to lithium, and development of a method to predict individual responses to lithium could thereby accelerate recovery and reduce suffering and cost [<xref rid="B104-ijms-18-02406" ref-type="bibr">104</xref>].</p><p>Neuroimaging, such as functional functional magnetic resonance imaging (fMRI) and positron emission tomography (PET), may reveal different responses in patients who respond well to a particular AD class or MS class, compared to those who do not respond. In PET of patients with unipolar depression, rostral anterior cingulate metabolism uniquely differentiated eventual treatment responders (hypermetabolism) from non-responders (hypometabolism) [<xref rid="B105-ijms-18-02406" ref-type="bibr">105</xref>]. Increased glucose metabolism in cortico-limbic circuitry revealed by PET was related to successful paroxetine treatment response [<xref rid="B106-ijms-18-02406" ref-type="bibr">106</xref>]. A recent fMRI study had better prognostic value than current practice based on clinical impressions [<xref rid="B107-ijms-18-02406" ref-type="bibr">107</xref>,<xref rid="B108-ijms-18-02406" ref-type="bibr">108</xref>]. Although various studies have examined the relationship between immune status, including various C-reactive protein or pro-inflammatory cytokines, and AD responsiveness, the results have been inconsistent. Peripheral blood inflammatory biomarkers may contribute to personalized treatment choice and improved AD outcomes [<xref rid="B109-ijms-18-02406" ref-type="bibr">109</xref>].</p><p>The effects of oxidative stress on mood disorders are shown to result in a down-regulation of anti-oxidant reactions in the hippocampus, such as superoxide dismutase, catalase, glutathione peroxidase, glutathione-<italic>S</italic>-transferase, and other genes [<xref rid="B110-ijms-18-02406" ref-type="bibr">110</xref>,<xref rid="B111-ijms-18-02406" ref-type="bibr">111</xref>]. Accumulation of oxidative damage to mitochondria in brain might lead neuronal cellular death as a result of aggregation of oxidized protein, which may result in neurodegeneration [<xref rid="B112-ijms-18-02406" ref-type="bibr">112</xref>]. In conclusion, to anticipate diagnostic differentiation of psychiatric illnesses and individual responses to classes of medication, and to realize personalized medicine, an understanding of the pathophysiology of depression and the development of simple and accessible biomarkers are required. To date, research on various basic sciences, such as genetic/epigenetic, proteomic, neuroimaging, and inflammatory factors, has been underway, and some candidate approaches have been suggested. However, no definite biomarker has yet been found and further studies are needed.</p></sec><sec id="sec6-ijms-18-02406"><title>6. Conclusions</title><p>Historically, bisection of mood disorders into MDDs and BDs has been relatively rapid. Additionally, the concept of bipolar spectrum and the proportion of shared features between MDDs and BDs has led to increasingly divergent diagnoses. Under these circumstances, cautious pharmacological treatment must be administered using ADs and MSs in MDEs and for long-term stability of BDs. For initial treatment of MDEs, screening tools (e.g., HCL-32, MDQ, SAD-P, YMRS), specific symptom evaluation through mental status examination, and careful history taking should be performed to distinguish bipolarity from mixed features for which AD monotherapy may represent a risk. Depending on the therapeutic response, the existing guidelines and the results of empirical research findings can be followed. Currently, AD monotherapy should be avoided in patients strongly suspected as having bipolar depression or MDDs with mixed features. In these patients, a combination or adjunctive treatment with MSs or AAPs is recommended when it is considered beneficial to use ADs. MS efficacy studies on bipolar depression suggest that lamotrigine is the most reliable; lithium is expected to have modest effects, and evidence is still lacking regarding the efficacy of valproate and carbamazepine. To prevent long-term episodic relapse in BDs, MSs may also be recommended, either alone or in combination with other MSs and AAPs. Despite these therapeutic efforts, mood disorders are chronic psychiatric illnesses that are frequently recurrent and difficult to treat. There is a continuing need for novel research and further development of these drugs. Recently, radical progress has been achieved in research into pathophysiology and biomarkers in the fields of molecular biology, genetic/epigenetics, and neuroimaging. There is also an opportunity to study novel drug mechanisms through the rediscovery of fast-acting drugs, including ketamine. Through this process, it is anticipated that research will develop in the direction of discovering potential targets for new drugs and applying them to personalized treatments.</p></sec></body><back><notes><title>Author Contributions</title><p>Authors In Hee Shim and Won-Myong Bahk designed the study and wrote the protocol; authors In Hee Shim, Young Sup Woo, Moon-Doo Kim, and Won-Myong Bahk managed the literature searches, summaries of previous related work; all authors participated in the collection of data, and the order of authors was determined according to their contribution; author In Hee Shim wrote the first draft of the manuscript; all authors contributed to and have approved the final manuscript.</p></notes><notes notes-type="COI-statement"><title>Conflicts of Interest</title><p>The authors declare no conflict of interest.</p></notes><ref-list><title>References</title><ref id="B1-ijms-18-02406"><label>1.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>ReferencesKennedy</surname><given-names>S.H.</given-names></name><name><surname>Lam</surname><given-names>R.W.</given-names></name><name><surname>McIntyre</surname><given-names>R.S.</given-names></name><name><surname>Tourjman</surname><given-names>S.V.</given-names></name><name><surname>Bhat</surname><given-names>V.</given-names></name><name><surname>Blier</surname><given-names>P.</given-names></name><name><surname>Hasnain</surname><given-names>M.</given-names></name><name><surname>Jollant</surname><given-names>F.</given-names></name><name><surname>Levitt</surname><given-names>A.J.</given-names></name><name><surname>MacQueen</surname><given-names>G.M.</given-names></name><etal/></person-group><article-title>Canadian Network for Mood and Anxiety Treatments (CANMAT) 2016 Clinical Guidelines for the Management of Adults with Major Depressive Disorder: Section 3. Pharmacological Treatments</article-title><source>Can. J. Psychiatry</source><year>2016</year><volume>61</volume><fpage>540</fpage><lpage>560</lpage><pub-id pub-id-type="pmid">27486148</pub-id></element-citation></ref><ref id="B2-ijms-18-02406"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Malhi</surname><given-names>G.S.</given-names></name><name><surname>Bassett</surname><given-names>D.</given-names></name><name><surname>Boyce</surname><given-names>P.</given-names></name><name><surname>Bryant</surname><given-names>R.</given-names></name><name><surname>Fitzgerald</surname><given-names>P.B.</given-names></name><name><surname>Fritz</surname><given-names>K.</given-names></name><name><surname>Hopwood</surname><given-names>M.</given-names></name><name><surname>Lyndon</surname><given-names>B.</given-names></name><name><surname>Mulder</surname><given-names>R.</given-names></name><name><surname>Murray</surname><given-names>G.</given-names></name></person-group><article-title>Royal Australian and New Zealand College of Psychiatrists clinical practice guidelines for mood disorders</article-title><source>Aust. N. Z. J. Psychiatry</source><year>2015</year><volume>49</volume><fpage>1087</fpage><lpage>1206</lpage><pub-id pub-id-type="doi">10.1177/0004867415617657</pub-id><?supplied-pmid 26643054?><pub-id pub-id-type="pmid">26643054</pub-id></element-citation></ref><ref id="B3-ijms-18-02406"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bauer</surname><given-names>M.</given-names></name><name><surname>Pfennig</surname><given-names>A.</given-names></name><name><surname>Severus</surname><given-names>E.</given-names></name><name><surname>Whybrow</surname><given-names>P.C.</given-names></name><name><surname>Angst</surname><given-names>J.</given-names></name><name><surname>Moller</surname><given-names>H.J.</given-names></name></person-group><article-title>World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of unipolar depressive disorders, part 1: Update 2013 on the acute and continuation treatment of unipolar depressive disorders</article-title><source>World J. Biol. Psychiatry</source><year>2013</year><volume>14</volume><fpage>334</fpage><lpage>385</lpage><pub-id pub-id-type="doi">10.3109/15622975.2013.804195</pub-id><?supplied-pmid 23879318?><pub-id pub-id-type="pmid">23879318</pub-id></element-citation></ref><ref id="B4-ijms-18-02406"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Woo</surname><given-names>Y.S.</given-names></name><name><surname>Lee</surname><given-names>J.G.</given-names></name><name><surname>Jeong</surname><given-names>J.-H.</given-names></name><name><surname>Kim</surname><given-names>M.-D.</given-names></name><name><surname>Sohn</surname><given-names>I.</given-names></name><name><surname>Shim</surname><given-names>S.-H.</given-names></name><name><surname>Jon</surname><given-names>D.-I.</given-names></name><name><surname>Seo</surname><given-names>J.S.</given-names></name><name><surname>Shin</surname><given-names>Y.-C.</given-names></name><name><surname>Min</surname><given-names>K.J.</given-names></name></person-group><article-title>Korean medication algorithm project for bipolar disorder: Third revision</article-title><source>Neuropsychiatr. Dis. Treat.</source><year>2015</year><volume>11</volume><fpage>493</fpage><?supplied-pmid 25750530?><pub-id pub-id-type="pmid">25750530</pub-id></element-citation></ref><ref id="B5-ijms-18-02406"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yatham</surname><given-names>L.N.</given-names></name><name><surname>Kennedy</surname><given-names>S.H.</given-names></name><name><surname>Parikh</surname><given-names>S.V.</given-names></name><name><surname>Schaffer</surname><given-names>A.</given-names></name><name><surname>Beaulieu</surname><given-names>S.</given-names></name><name><surname>Alda</surname><given-names>M.</given-names></name><name><surname>O&#x02019;Donovan</surname><given-names>C.</given-names></name><name><surname>MacQueen</surname><given-names>G.</given-names></name><name><surname>McIntyre</surname><given-names>R.S.</given-names></name><name><surname>Sharma</surname><given-names>V.</given-names></name></person-group><article-title>Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) collaborative update of CANMAT guidelines for the management of patients with bipolar disorder: Update 2013</article-title><source>Bipolar Disord.</source><year>2013</year><volume>15</volume><fpage>1</fpage><lpage>44</lpage><pub-id pub-id-type="doi">10.1111/bdi.12025</pub-id><?supplied-pmid 23237061?><pub-id pub-id-type="pmid">23237061</pub-id></element-citation></ref><ref id="B6-ijms-18-02406"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Grunze</surname><given-names>H.</given-names></name><name><surname>Vieta</surname><given-names>E.</given-names></name><name><surname>Goodwin</surname><given-names>G.M.</given-names></name><name><surname>Bowden</surname><given-names>C.</given-names></name><name><surname>Licht</surname><given-names>R.W.</given-names></name><name><surname>M&#x000f6;ller</surname><given-names>H.-J.</given-names></name><name><surname>Kasper</surname><given-names>S.</given-names></name><name><surname>Grunze</surname><given-names>H.</given-names></name><name><surname>Vieta</surname><given-names>E.</given-names></name></person-group><article-title>The World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the biological treatment of bipolar disorders: Update 2009 on the treatment of acute mania</article-title><source>World J. Biol. Psychiatry</source><year>2009</year><volume>10</volume><fpage>85</fpage><lpage>116</lpage><pub-id pub-id-type="doi">10.1080/15622970902823202</pub-id><?supplied-pmid 19347775?><pub-id pub-id-type="pmid">19347775</pub-id></element-citation></ref><ref id="B7-ijms-18-02406"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Grunze</surname><given-names>H.</given-names></name><name><surname>Vieta</surname><given-names>E.</given-names></name><name><surname>Goodwin</surname><given-names>G.M.</given-names></name><name><surname>Bowden</surname><given-names>C.</given-names></name><name><surname>Licht</surname><given-names>R.W.</given-names></name><name><surname>M&#x000f6;ller</surname><given-names>H.-J.</given-names></name><name><surname>Kasper</surname><given-names>S.</given-names></name></person-group><article-title>The World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the biological treatment of bipolar disorders: Update 2012 on the long-term treatment of bipolar disorder</article-title><source>World J. Biol. Psychiatry</source><year>2013</year><volume>14</volume><fpage>154</fpage><lpage>219</lpage><pub-id pub-id-type="doi">10.3109/15622975.2013.770551</pub-id><?supplied-pmid 23480132?><pub-id pub-id-type="pmid">23480132</pub-id></element-citation></ref><ref id="B8-ijms-18-02406"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pacchiarotti</surname><given-names>I.</given-names></name><name><surname>Bond</surname><given-names>D.J.</given-names></name><name><surname>Baldessarini</surname><given-names>R.J.</given-names></name><name><surname>Nolen</surname><given-names>W.A.</given-names></name><name><surname>Grunze</surname><given-names>H.</given-names></name><name><surname>Licht</surname><given-names>R.W.</given-names></name><name><surname>Post</surname><given-names>R.M.</given-names></name><name><surname>Berk</surname><given-names>M.</given-names></name><name><surname>Goodwin</surname><given-names>G.M.</given-names></name><name><surname>Sachs</surname><given-names>G.S.</given-names></name><etal/></person-group><article-title>The International Society for Bipolar Disorders (ISBD) task force report on antidepressant use in bipolar disorders</article-title><source>Am. J. Psychiatry</source><year>2013</year><volume>170</volume><fpage>1249</fpage><lpage>1262</lpage><pub-id pub-id-type="doi">10.1176/appi.ajp.2013.13020185</pub-id><?supplied-pmid 24030475?><pub-id pub-id-type="pmid">24030475</pub-id></element-citation></ref><ref id="B9-ijms-18-02406"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ghaemi</surname><given-names>S.N.</given-names></name><name><surname>Wingo</surname><given-names>A.P.</given-names></name><name><surname>Filkowski</surname><given-names>M.A.</given-names></name><name><surname>Baldessarini</surname><given-names>R.J.</given-names></name></person-group><article-title>Long-term antidepressant treatment in bipolar disorder: Meta-analyses of benefits and risks</article-title><source>Acta Psychiatr. Scand.</source><year>2008</year><volume>118</volume><fpage>347</fpage><lpage>356</lpage><pub-id pub-id-type="doi">10.1111/j.1600-0447.2008.01257.x</pub-id><?supplied-pmid 18727689?><pub-id pub-id-type="pmid">18727689</pub-id></element-citation></ref><ref id="B10-ijms-18-02406"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lish</surname><given-names>J.D.</given-names></name><name><surname>Dime-Meenan</surname><given-names>S.</given-names></name><name><surname>Whybrow</surname><given-names>P.C.</given-names></name><name><surname>Price</surname><given-names>R.A.</given-names></name><name><surname>Hirschfeld</surname><given-names>R.M.</given-names></name></person-group><article-title>The National Depressive and Manic-depressive Association (DMDA) survey of bipolar members</article-title><source>J. Affect. Disord.</source><year>1994</year><volume>31</volume><fpage>281</fpage><lpage>294</lpage><pub-id pub-id-type="doi">10.1016/0165-0327(94)90104-X</pub-id><pub-id pub-id-type="pmid">7989643</pub-id></element-citation></ref><ref id="B11-ijms-18-02406"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hirschfeld</surname><given-names>R.M.</given-names></name><name><surname>Lewis</surname><given-names>L.</given-names></name><name><surname>Vornik</surname><given-names>L.A.</given-names></name></person-group><article-title>Perceptions and impact of bipolar disorder: How far have we really come? Results of the national depressive and manic-depressive association 2000 survey of individuals with bipolar disorder</article-title><source>J. Clin. Psychiatry</source><year>2003</year><volume>64</volume><fpage>161</fpage><lpage>174</lpage><pub-id pub-id-type="doi">10.4088/JCP.v64n0209</pub-id><?supplied-pmid 12633125?><pub-id pub-id-type="pmid">12633125</pub-id></element-citation></ref><ref id="B12-ijms-18-02406"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Morselli</surname><given-names>P.L.</given-names></name><name><surname>Elgie</surname><given-names>R.</given-names></name></person-group><article-title>GAMIAN-Europe/BEAM survey I&#x02014;Global analysis of a patient questionnaire circulated to 3450 members of 12 European advocacy groups operating in the field of mood disorders</article-title><source>Bipolar Disord.</source><year>2003</year><volume>5</volume><fpage>265</fpage><lpage>278</lpage><pub-id pub-id-type="doi">10.1034/j.1399-5618.2003.00037.x</pub-id><?supplied-pmid 12895204?><pub-id pub-id-type="pmid">12895204</pub-id></element-citation></ref><ref id="B13-ijms-18-02406"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ghaemi</surname><given-names>S.N.</given-names></name><name><surname>Sachs</surname><given-names>G.S.</given-names></name><name><surname>Chiou</surname><given-names>A.M.</given-names></name><name><surname>Pandurangi</surname><given-names>A.K.</given-names></name><name><surname>Goodwin</surname><given-names>K.</given-names></name></person-group><article-title>Is bipolar disorder still underdiagnosed? Are antidepressants overutilized?</article-title><source>J. Affect. Disord.</source><year>1999</year><volume>52</volume><fpage>135</fpage><lpage>144</lpage><pub-id pub-id-type="doi">10.1016/S0165-0327(98)00076-7</pub-id><pub-id pub-id-type="pmid">10357026</pub-id></element-citation></ref><ref id="B14-ijms-18-02406"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cuellar</surname><given-names>A.K.</given-names></name><name><surname>Johnson</surname><given-names>S.L.</given-names></name><name><surname>Winters</surname><given-names>R.</given-names></name></person-group><article-title>Distinctions between bipolar and unipolar depression</article-title><source>Clin. Psychol. Rev.</source><year>2005</year><volume>25</volume><fpage>307</fpage><lpage>339</lpage><pub-id pub-id-type="doi">10.1016/j.cpr.2004.12.002</pub-id><?supplied-pmid 15792852?><pub-id pub-id-type="pmid">15792852</pub-id></element-citation></ref><ref id="B15-ijms-18-02406"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mitchell</surname><given-names>P.B.</given-names></name><name><surname>Goodwin</surname><given-names>G.M.</given-names></name><name><surname>Johnson</surname><given-names>G.F.</given-names></name><name><surname>Hirschfeld</surname><given-names>R.</given-names></name></person-group><article-title>Diagnostic guidelines for bipolar depression: A probabilistic approach</article-title><source>Bipolar Disord.</source><year>2008</year><volume>10</volume><fpage>144</fpage><lpage>152</lpage><pub-id pub-id-type="doi">10.1111/j.1399-5618.2007.00559.x</pub-id><?supplied-pmid 18199233?><pub-id pub-id-type="pmid">18199233</pub-id></element-citation></ref><ref id="B16-ijms-18-02406"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pini</surname><given-names>S.</given-names></name><name><surname>de Queiroz</surname><given-names>V.</given-names></name><name><surname>Pagnin</surname><given-names>D.</given-names></name><name><surname>Pezawas</surname><given-names>L.</given-names></name><name><surname>Angst</surname><given-names>J.</given-names></name><name><surname>Cassano</surname><given-names>G.B.</given-names></name><name><surname>Wittchen</surname><given-names>H.-U.</given-names></name></person-group><article-title>Prevalence and burden of bipolar disorders in European countries</article-title><source>Eur. Neuropsychopharmacol.</source><year>2005</year><volume>15</volume><fpage>425</fpage><lpage>434</lpage><pub-id pub-id-type="doi">10.1016/j.euroneuro.2005.04.011</pub-id><?supplied-pmid 15935623?><pub-id pub-id-type="pmid">15935623</pub-id></element-citation></ref><ref id="B17-ijms-18-02406"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Perlis</surname><given-names>R.H.</given-names></name><name><surname>Brown</surname><given-names>E.</given-names></name><name><surname>Baker</surname><given-names>R.W.</given-names></name><name><surname>Nierenberg</surname><given-names>A.A.</given-names></name></person-group><article-title>Clinical features of bipolar depression versus major depressive disorder in large multicenter trials</article-title><source>Am. J. Psychiatry</source><year>2006</year><volume>163</volume><fpage>225</fpage><lpage>231</lpage><pub-id pub-id-type="doi">10.1176/appi.ajp.163.2.225</pub-id><?supplied-pmid 16449475?><pub-id pub-id-type="pmid">16449475</pub-id></element-citation></ref><ref id="B18-ijms-18-02406"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Forty</surname><given-names>L.</given-names></name><name><surname>Jones</surname><given-names>L.</given-names></name><name><surname>Jones</surname><given-names>I.</given-names></name><name><surname>Smith</surname><given-names>D.J.</given-names></name><name><surname>Caesar</surname><given-names>S.</given-names></name><name><surname>Fraser</surname><given-names>C.</given-names></name><name><surname>Gordon-Smith</surname><given-names>K.</given-names></name><name><surname>Hyde</surname><given-names>S.</given-names></name><name><surname>Craddock</surname><given-names>N.</given-names></name></person-group><article-title>Polarity at illness onset in bipolar I disorder and clinical course of illness</article-title><source>Bipolar Disord.</source><year>2009</year><volume>11</volume><fpage>82</fpage><lpage>88</lpage><pub-id pub-id-type="doi">10.1111/j.1399-5618.2008.00654.x</pub-id><?supplied-pmid 19133970?><pub-id pub-id-type="pmid">19133970</pub-id></element-citation></ref><ref id="B19-ijms-18-02406"><label>19.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Winokur</surname><given-names>G.</given-names></name><name><surname>Coryell</surname><given-names>W.</given-names></name><name><surname>Keller</surname><given-names>M.</given-names></name><name><surname>Endicott</surname><given-names>J.</given-names></name><name><surname>Leon</surname><given-names>A.</given-names></name></person-group><article-title>A family study of manic-depressive (bipolar I) disease: Is it a distinct illness separable from primary unipolar depression?</article-title><source>Arch. Gen. Psychiatry</source><year>1995</year><volume>52</volume><fpage>367</fpage><lpage>373</lpage><pub-id pub-id-type="doi">10.1001/archpsyc.1995.03950170041006</pub-id><?supplied-pmid 7726717?><pub-id pub-id-type="pmid">7726717</pub-id></element-citation></ref><ref id="B20-ijms-18-02406"><label>20.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cassidy</surname><given-names>F.</given-names></name><name><surname>Ahearn</surname><given-names>E.P.</given-names></name><name><surname>Carroll</surname><given-names>B.J.</given-names></name></person-group><article-title>Substance abuse in bipolar disorder</article-title><source>Bipolar Disord.</source><year>2001</year><volume>3</volume><fpage>181</fpage><lpage>188</lpage><pub-id pub-id-type="doi">10.1034/j.1399-5618.2001.30403.x</pub-id><?supplied-pmid 11552957?><pub-id pub-id-type="pmid">11552957</pub-id></element-citation></ref><ref id="B21-ijms-18-02406"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kelly</surname><given-names>E.</given-names></name><name><surname>Sharma</surname><given-names>V.</given-names></name></person-group><article-title>Diagnosis and treatment of postpartum bipolar depression</article-title><source>Expert Rev. Neurother.</source><year>2010</year><volume>10</volume><fpage>1045</fpage><lpage>1051</lpage><pub-id pub-id-type="doi">10.1586/ern.10.81</pub-id><?supplied-pmid 20586688?><pub-id pub-id-type="pmid">20586688</pub-id></element-citation></ref><ref id="B22-ijms-18-02406"><label>22.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Reinares</surname><given-names>M.</given-names></name><name><surname>Vieta</surname><given-names>E.</given-names></name></person-group><article-title>Course and outcome patterns of depression: From unipolar episode to bipolar disorder</article-title><source>Medicographia</source><year>2011</year><volume>33</volume><fpage>145</fpage><lpage>150</lpage></element-citation></ref><ref id="B23-ijms-18-02406"><label>23.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tohen</surname><given-names>M.</given-names></name><name><surname>Zarate</surname><given-names>C.A.</given-names><suffix>Jr.</suffix></name><name><surname>Hennen</surname><given-names>J.</given-names></name><name><surname>Khalsa</surname><given-names>H.M.</given-names></name><name><surname>Strakowski</surname><given-names>S.M.</given-names></name><name><surname>Gebre-Medhin</surname><given-names>P.</given-names></name><name><surname>Salvatore</surname><given-names>P.</given-names></name><name><surname>Baldessarini</surname><given-names>R.J.</given-names></name></person-group><article-title>The McLean-Harvard First-Episode Mania Study: Prediction of recovery and first recurrence</article-title><source>Am. J. Psychiatry</source><year>2003</year><volume>160</volume><fpage>2099</fpage><lpage>2107</lpage><pub-id pub-id-type="doi">10.1176/appi.ajp.160.12.2099</pub-id><?supplied-pmid 14638578?><pub-id pub-id-type="pmid">14638578</pub-id></element-citation></ref><ref id="B24-ijms-18-02406"><label>24.</label><element-citation publication-type="book"><person-group person-group-type="author"><collab>National Collaborating Centre for Mental Health</collab></person-group><article-title>National Collaborating Centre for Mental Health. National Institute for Health and Clinical Excellence: Guidance</article-title><source>Depression: The Treatment and Management of Depression in Adults (Updated Edition)</source><publisher-name>The British Psychological Society &#x00026; The Royal College of Psychiatrists</publisher-name><publisher-loc>Leicester, UK</publisher-loc><year>2010</year></element-citation></ref><ref id="B25-ijms-18-02406"><label>25.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>H.R.</given-names></name><name><surname>Bahk</surname><given-names>W.M.</given-names></name><name><surname>Seo</surname><given-names>J.S.</given-names></name><name><surname>Woo</surname><given-names>Y.S.</given-names></name><name><surname>Park</surname><given-names>Y.M.</given-names></name><name><surname>Jeong</surname><given-names>J.H.</given-names></name><name><surname>Kim</surname><given-names>W.</given-names></name><name><surname>Shim</surname><given-names>S.H.</given-names></name><name><surname>Lee</surname><given-names>J.G.</given-names></name><name><surname>Jon</surname><given-names>D.I.</given-names></name><etal/></person-group><article-title>Korean medication algorithm for depressive disorder: Comparisons with other treatment guidelines</article-title><source>Clin. Psychopharmacol. Neurosci.</source><year>2017</year><volume>15</volume><fpage>199</fpage><lpage>209</lpage><pub-id pub-id-type="doi">10.9758/cpn.2017.15.3.199</pub-id><?supplied-pmid 28783928?><pub-id pub-id-type="pmid">28783928</pub-id></element-citation></ref><ref id="B26-ijms-18-02406"><label>26.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Baldessarini</surname><given-names>R.J.</given-names></name><name><surname>Leahy</surname><given-names>L.</given-names></name><name><surname>Arcona</surname><given-names>S.</given-names></name><name><surname>Gause</surname><given-names>D.</given-names></name><name><surname>Zhang</surname><given-names>W.</given-names></name><name><surname>Hennen</surname><given-names>J.</given-names></name></person-group><article-title>Patterns of psychotropic drug prescription for U.S. patients with diagnoses of bipolar disorders</article-title><source>Psychiatr. Serv.</source><year>2007</year><volume>58</volume><fpage>85</fpage><lpage>91</lpage><pub-id pub-id-type="doi">10.1176/ps.2007.58.1.85</pub-id><?supplied-pmid 17215417?><pub-id pub-id-type="pmid">17215417</pub-id></element-citation></ref><ref id="B27-ijms-18-02406"><label>27.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Greil</surname><given-names>W.</given-names></name><name><surname>Haberle</surname><given-names>A.</given-names></name><name><surname>Haueis</surname><given-names>P.</given-names></name><name><surname>Grohmann</surname><given-names>R.</given-names></name><name><surname>Russmann</surname><given-names>S.</given-names></name></person-group><article-title>Pharmacotherapeutic trends in 2231 psychiatric inpatients with bipolar depression from the International AMSP Project between 1994 and 2009</article-title><source>J. Affect. Disord.</source><year>2012</year><volume>136</volume><fpage>534</fpage><lpage>542</lpage><pub-id pub-id-type="doi">10.1016/j.jad.2011.10.033</pub-id><?supplied-pmid 22134044?><pub-id pub-id-type="pmid">22134044</pub-id></element-citation></ref><ref id="B28-ijms-18-02406"><label>28.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Amsterdam</surname><given-names>J.D.</given-names></name><name><surname>Shults</surname><given-names>J.</given-names></name></person-group><article-title>Comparison of fluoxetine, olanzapine, and combined fluoxetine plus olanzapine initial therapy of bipolar type I and type II major depression&#x02014;lack of manic induction</article-title><source>J. Affect. Disord.</source><year>2005</year><volume>87</volume><fpage>121</fpage><lpage>130</lpage><pub-id pub-id-type="doi">10.1016/j.jad.2005.02.018</pub-id><?supplied-pmid 15923042?><pub-id pub-id-type="pmid">15923042</pub-id></element-citation></ref><ref id="B29-ijms-18-02406"><label>29.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Amsterdam</surname><given-names>J.D.</given-names></name><name><surname>Lorenzo-Luaces</surname><given-names>L.</given-names></name><name><surname>Soeller</surname><given-names>I.</given-names></name><name><surname>Li</surname><given-names>S.Q.</given-names></name><name><surname>Mao</surname><given-names>J.J.</given-names></name><name><surname>DeRubeis</surname><given-names>R.J.</given-names></name></person-group><article-title>Safety and effectiveness of continuation antidepressant versus mood stabilizer monotherapy for relapse-prevention of bipolar II depression: A randomized, double-blind, parallel-group, prospective study</article-title><source>J. Affect. Disord.</source><year>2015</year><volume>185</volume><fpage>31</fpage><lpage>37</lpage><pub-id pub-id-type="doi">10.1016/j.jad.2015.05.070</pub-id><?supplied-pmid 26143402?><pub-id pub-id-type="pmid">26143402</pub-id></element-citation></ref><ref id="B30-ijms-18-02406"><label>30.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Amsterdam</surname><given-names>J.D.</given-names></name><name><surname>Shults</surname><given-names>J.</given-names></name></person-group><article-title>Comparison of short-term venlafaxine versus lithium monotherapy for bipolar II major depressive episode: A randomized open-label study</article-title><source>J. Clin. Psychopharmacol.</source><year>2008</year><volume>28</volume><fpage>171</fpage><lpage>181</lpage><pub-id pub-id-type="doi">10.1097/JCP.0b013e318166c4e6</pub-id><?supplied-pmid 18344727?><pub-id pub-id-type="pmid">18344727</pub-id></element-citation></ref><ref id="B31-ijms-18-02406"><label>31.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McElroy</surname><given-names>S.L.</given-names></name><name><surname>Weisler</surname><given-names>R.H.</given-names></name><name><surname>Chang</surname><given-names>W.</given-names></name><name><surname>Olausson</surname><given-names>B.</given-names></name><name><surname>Paulsson</surname><given-names>B.</given-names></name><name><surname>Brecher</surname><given-names>M.</given-names></name><name><surname>Agambaram</surname><given-names>V.</given-names></name><name><surname>Merideth</surname><given-names>C.</given-names></name><name><surname>Nordenhem</surname><given-names>A.</given-names></name><name><surname>Young</surname><given-names>A.H.</given-names></name></person-group><article-title>A double-blind, placebo-controlled study of quetiapine and paroxetine as monotherapy in adults with bipolar depression (EMBOLDEN II)</article-title><source>J. Clin. Psychiatry</source><year>2010</year><volume>71</volume><fpage>163</fpage><lpage>174</lpage><pub-id pub-id-type="doi">10.4088/JCP.08m04942gre</pub-id><?supplied-pmid 20122366?><pub-id pub-id-type="pmid">20122366</pub-id></element-citation></ref><ref id="B32-ijms-18-02406"><label>32.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vazquez</surname><given-names>G.H.</given-names></name><name><surname>Tondo</surname><given-names>L.</given-names></name><name><surname>Undurraga</surname><given-names>J.</given-names></name><name><surname>Baldessarini</surname><given-names>R.J.</given-names></name></person-group><article-title>Overview of antidepressant treatment of bipolar depression</article-title><source>Int. J. Neuropsychopharmacol.</source><year>2013</year><volume>16</volume><fpage>1673</fpage><lpage>1685</lpage><pub-id pub-id-type="doi">10.1017/S1461145713000023</pub-id><?supplied-pmid 23428003?><pub-id pub-id-type="pmid">23428003</pub-id></element-citation></ref><ref id="B33-ijms-18-02406"><label>33.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sidor</surname><given-names>M.M.</given-names></name><name><surname>Macqueen</surname><given-names>G.M.</given-names></name></person-group><article-title>Antidepressants for the acute treatment of bipolar depression: A systematic review and meta-analysis</article-title><source>J. Clin. Psychiatry</source><year>2011</year><volume>72</volume><fpage>156</fpage><lpage>167</lpage><pub-id pub-id-type="doi">10.4088/JCP.09r05385gre</pub-id><?supplied-pmid 21034686?><pub-id pub-id-type="pmid">21034686</pub-id></element-citation></ref><ref id="B34-ijms-18-02406"><label>34.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tohen</surname><given-names>M.</given-names></name><name><surname>Vieta</surname><given-names>E.</given-names></name><name><surname>Calabrese</surname><given-names>J.</given-names></name><name><surname>Ketter</surname><given-names>T.A.</given-names></name><name><surname>Sachs</surname><given-names>G.</given-names></name><name><surname>Bowden</surname><given-names>C.</given-names></name><name><surname>Mitchell</surname><given-names>P.B.</given-names></name><name><surname>Centorrino</surname><given-names>F.</given-names></name><name><surname>Risser</surname><given-names>R.</given-names></name><name><surname>Baker</surname><given-names>R.W.</given-names></name><etal/></person-group><article-title>Efficacy of olanzapine and olanzapine-fluoxetine combination in the treatment of bipolar I depression</article-title><source>Arch. Gen. Psychiatry</source><year>2003</year><volume>60</volume><fpage>1079</fpage><lpage>1088</lpage><pub-id pub-id-type="doi">10.1001/archpsyc.60.11.1079</pub-id><?supplied-pmid 14609883?><pub-id pub-id-type="pmid">14609883</pub-id></element-citation></ref><ref id="B35-ijms-18-02406"><label>35.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Brown</surname><given-names>E.B.</given-names></name><name><surname>McElroy</surname><given-names>S.L.</given-names></name><name><surname>Keck</surname><given-names>P.E.</given-names><suffix>Jr.</suffix></name><name><surname>Deldar</surname><given-names>A.</given-names></name><name><surname>Adams</surname><given-names>D.H.</given-names></name><name><surname>Tohen</surname><given-names>M.</given-names></name><name><surname>Williamson</surname><given-names>D.J.</given-names></name></person-group><article-title>A 7-week, randomized, double-blind trial of olanzapine/fluoxetine combination versus lamotrigine in the treatment of bipolar I depression</article-title><source>J. Clin. Psychiatry</source><year>2006</year><volume>67</volume><fpage>1025</fpage><lpage>1033</lpage><pub-id pub-id-type="doi">10.4088/JCP.v67n0703</pub-id><?supplied-pmid 16889444?><pub-id pub-id-type="pmid">16889444</pub-id></element-citation></ref><ref id="B36-ijms-18-02406"><label>36.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sachs</surname><given-names>G.S.</given-names></name><name><surname>Nierenberg</surname><given-names>A.A.</given-names></name><name><surname>Calabrese</surname><given-names>J.R.</given-names></name><name><surname>Marangell</surname><given-names>L.B.</given-names></name><name><surname>Wisniewski</surname><given-names>S.R.</given-names></name><name><surname>Gyulai</surname><given-names>L.</given-names></name><name><surname>Friedman</surname><given-names>E.S.</given-names></name><name><surname>Bowden</surname><given-names>C.L.</given-names></name><name><surname>Fossey</surname><given-names>M.D.</given-names></name><name><surname>Ostacher</surname><given-names>M.J.</given-names></name><etal/></person-group><article-title>Effectiveness of adjunctive antidepressant treatment for bipolar depression</article-title><source>N. Engl. J. Med.</source><year>2007</year><volume>356</volume><fpage>1711</fpage><lpage>1722</lpage><?supplied-pmid 17392295?><pub-id pub-id-type="pmid">17392295</pub-id></element-citation></ref><ref id="B37-ijms-18-02406"><label>37.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yatham</surname><given-names>L.N.</given-names></name><name><surname>Vieta</surname><given-names>E.</given-names></name><name><surname>Goodwin</surname><given-names>G.M.</given-names></name><name><surname>Bourin</surname><given-names>M.</given-names></name><name><surname>de Bodinat</surname><given-names>C.</given-names></name><name><surname>Laredo</surname><given-names>J.</given-names></name><name><surname>Calabrese</surname><given-names>J.</given-names></name></person-group><article-title>Agomelatine or placebo as adjunctive therapy to a mood stabiliser in bipolar I depression: Randomised double-blind placebo-controlled trial</article-title><source>Br. J. Psychiatry</source><year>2016</year><volume>208</volume><fpage>78</fpage><lpage>86</lpage><pub-id pub-id-type="doi">10.1192/bjp.bp.114.147587</pub-id><?supplied-pmid 25999335?><pub-id pub-id-type="pmid">25999335</pub-id></element-citation></ref><ref id="B38-ijms-18-02406"><label>38.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bocchetta</surname><given-names>A.</given-names></name><name><surname>Bernardi</surname><given-names>F.</given-names></name><name><surname>Burrai</surname><given-names>C.</given-names></name><name><surname>Pedditzi</surname><given-names>M.</given-names></name><name><surname>del Zompo</surname><given-names>M.</given-names></name></person-group><article-title>A double-blind study of <sc>l</sc>-sulpiride versus amitriptyline in lithium-maintained bipolar depressives</article-title><source>Acta Psychiatr. Scand.</source><year>1993</year><volume>88</volume><fpage>434</fpage><lpage>439</lpage><pub-id pub-id-type="doi">10.1111/j.1600-0447.1993.tb03487.x</pub-id><?supplied-pmid 8310852?><pub-id pub-id-type="pmid">8310852</pub-id></element-citation></ref><ref id="B39-ijms-18-02406"><label>39.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Agosti</surname><given-names>V.</given-names></name><name><surname>Stewart</surname><given-names>J.W.</given-names></name></person-group><article-title>Efficacy and safety of antidepressant monotherapy in the treatment of bipolar-II depression</article-title><source>Int. Clin. Psychopharmacol.</source><year>2007</year><volume>22</volume><fpage>309</fpage><lpage>311</lpage><pub-id pub-id-type="doi">10.1097/YIC.0b013e3280c28410</pub-id><?supplied-pmid 17690600?><pub-id pub-id-type="pmid">17690600</pub-id></element-citation></ref><ref id="B40-ijms-18-02406"><label>40.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Himmelhoch</surname><given-names>J.M.</given-names></name><name><surname>Thase</surname><given-names>M.E.</given-names></name><name><surname>Mallinger</surname><given-names>A.G.</given-names></name><name><surname>Houck</surname><given-names>P.</given-names></name></person-group><article-title>Tranylcypromine versus imipramine in anergic bipolar depression</article-title><source>Am. J. Psychiatry</source><year>1991</year><volume>148</volume><fpage>910</fpage><lpage>916</lpage><?supplied-pmid 2053632?><pub-id pub-id-type="pmid">2053632</pub-id></element-citation></ref><ref id="B41-ijms-18-02406"><label>41.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Thase</surname><given-names>M.E.</given-names></name><name><surname>Mallinger</surname><given-names>A.G.</given-names></name></person-group><article-title>Treatment of imipramine-resistant recurrent depression, IV: A double-blind crossover study of tranylcypromine for anergic bipolar depression</article-title><source>Am. J. Psychiatry</source><year>1992</year><volume>149</volume><fpage>195</fpage><?supplied-pmid 1734739?><pub-id pub-id-type="pmid">1734739</pub-id></element-citation></ref><ref id="B42-ijms-18-02406"><label>42.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Silverstone</surname><given-names>T.</given-names></name></person-group><article-title>Moclobemide vs. imipramine in bipolar depression: A multicentre double-blind clinical trial</article-title><source>Acta Psychiatr. Scand.</source><year>2001</year><volume>104</volume><fpage>104</fpage><lpage>109</lpage><pub-id pub-id-type="doi">10.1034/j.1600-0447.2001.00240.x</pub-id><?supplied-pmid 11473503?><pub-id pub-id-type="pmid">11473503</pub-id></element-citation></ref><ref id="B43-ijms-18-02406"><label>43.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cohn</surname><given-names>J.B.</given-names></name><name><surname>Collins</surname><given-names>G.</given-names></name><name><surname>Ashbrook</surname><given-names>E.</given-names></name><name><surname>Wernicke</surname><given-names>J.F.</given-names></name></person-group><article-title>A comparison of fluoxetine imipramine and placebo in patients with bipolar depressive disorder</article-title><source>Int. Clin. Psychopharmacol.</source><year>1989</year><volume>4</volume><fpage>313</fpage><lpage>322</lpage><pub-id pub-id-type="doi">10.1097/00004850-198910000-00006</pub-id><?supplied-pmid 2607128?><pub-id pub-id-type="pmid">2607128</pub-id></element-citation></ref><ref id="B44-ijms-18-02406"><label>44.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nemeroff</surname><given-names>C.B.</given-names></name><name><surname>Evans</surname><given-names>D.L.</given-names></name><name><surname>Gyulai</surname><given-names>L.</given-names></name><name><surname>Sachs</surname><given-names>G.S.</given-names></name><name><surname>Bowden</surname><given-names>C.L.</given-names></name><name><surname>Gergel</surname><given-names>I.P.</given-names></name><name><surname>Oakes</surname><given-names>R.</given-names></name><name><surname>Pitts</surname><given-names>C.D.</given-names></name></person-group><article-title>Double-blind, placebo-controlled comparison of imipramine and paroxetine in the treatment of bipolar depression</article-title><source>Am. J. Psychiatry</source><year>2001</year><volume>158</volume><fpage>906</fpage><lpage>912</lpage><pub-id pub-id-type="doi">10.1176/appi.ajp.158.6.906</pub-id><?supplied-pmid 11384898?><pub-id pub-id-type="pmid">11384898</pub-id></element-citation></ref><ref id="B45-ijms-18-02406"><label>45.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Altshuler</surname><given-names>L.L.</given-names></name><name><surname>Sugar</surname><given-names>C.A.</given-names></name><name><surname>McElroy</surname><given-names>S.L.</given-names></name><name><surname>Calimlim</surname><given-names>B.</given-names></name><name><surname>Gitlin</surname><given-names>M.</given-names></name><name><surname>Keck</surname><given-names>P.E.</given-names><suffix>Jr.</suffix></name><name><surname>Aquino-Elias</surname><given-names>A.</given-names></name><name><surname>Martens</surname><given-names>B.E.</given-names></name><name><surname>Fischer</surname><given-names>E.G.</given-names></name><name><surname>English</surname><given-names>T.L.</given-names></name><etal/></person-group><article-title>Switch rates during acute treatment for bipolar ii depression with lithium, sertraline, or the two combined: A randomized double-blind comparison</article-title><source>Am. J. Psychiatry</source><year>2017</year><volume>174</volume><fpage>266</fpage><lpage>276</lpage><pub-id pub-id-type="doi">10.1176/appi.ajp.2016.15040558</pub-id><?supplied-pmid 28135846?><pub-id pub-id-type="pmid">28135846</pub-id></element-citation></ref><ref id="B46-ijms-18-02406"><label>46.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Young</surname><given-names>L.T.</given-names></name><name><surname>Joffe</surname><given-names>R.T.</given-names></name><name><surname>Robb</surname><given-names>J.C.</given-names></name><name><surname>MacQueen</surname><given-names>G.M.</given-names></name><name><surname>Marriott</surname><given-names>M.</given-names></name><name><surname>Patelis-Siotis</surname><given-names>I.</given-names></name></person-group><article-title>Double-blind comparison of addition of a second mood stabilizer versus an antidepressant to an initial mood stabilizer for treatment of patients with bipolar depression</article-title><source>Am. J. Psychiatry</source><year>2000</year><volume>157</volume><fpage>124</fpage><lpage>126</lpage><pub-id pub-id-type="doi">10.1176/ajp.157.1.124</pub-id><?supplied-pmid 10618026?><pub-id pub-id-type="pmid">10618026</pub-id></element-citation></ref><ref id="B47-ijms-18-02406"><label>47.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vieta</surname><given-names>E.</given-names></name><name><surname>Martinez-Aran</surname><given-names>A.</given-names></name><name><surname>Goikolea</surname><given-names>J.M.</given-names></name><name><surname>Torrent</surname><given-names>C.</given-names></name><name><surname>Colom</surname><given-names>F.</given-names></name><name><surname>Benabarre</surname><given-names>A.</given-names></name><name><surname>Reinares</surname><given-names>M.</given-names></name></person-group><article-title>A randomized trial comparing paroxetine and venlafaxine in the treatment of bipolar depressed patients taking mood stabilizers</article-title><source>J. Clin. Psychiatry</source><year>2002</year><volume>63</volume><fpage>508</fpage><lpage>512</lpage><pub-id pub-id-type="doi">10.4088/JCP.v63n0607</pub-id><?supplied-pmid 12088162?><pub-id pub-id-type="pmid">12088162</pub-id></element-citation></ref><ref id="B48-ijms-18-02406"><label>48.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shelton</surname><given-names>R.C.</given-names></name><name><surname>Stahl</surname><given-names>S.M.</given-names></name></person-group><article-title>Risperidone and paroxetine given singly and in combination for bipolar depression</article-title><source>J. Clin. Psychiatry</source><year>2004</year><volume>65</volume><fpage>1715</fpage><lpage>1719</lpage><pub-id pub-id-type="doi">10.4088/JCP.v65n1218</pub-id><?supplied-pmid 15641878?><pub-id pub-id-type="pmid">15641878</pub-id></element-citation></ref><ref id="B49-ijms-18-02406"><label>49.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Post</surname><given-names>R.M.</given-names></name><name><surname>Altshuler</surname><given-names>L.L.</given-names></name><name><surname>Leverich</surname><given-names>G.S.</given-names></name><name><surname>Frye</surname><given-names>M.A.</given-names></name><name><surname>Nolen</surname><given-names>W.A.</given-names></name><name><surname>Kupka</surname><given-names>R.W.</given-names></name><name><surname>Suppes</surname><given-names>T.</given-names></name><name><surname>McElroy</surname><given-names>S.</given-names></name><name><surname>Keck</surname><given-names>P.E.</given-names></name><name><surname>Denicoff</surname><given-names>K.D.</given-names></name><etal/></person-group><article-title>Mood switch in bipolar depression: Comparison of adjunctive venlafaxine, bupropion and sertraline</article-title><source>Br. J. Psychiatry</source><year>2006</year><volume>189</volume><fpage>124</fpage><lpage>131</lpage><pub-id pub-id-type="doi">10.1192/bjp.bp.105.013045</pub-id><?supplied-pmid 16880481?><pub-id pub-id-type="pmid">16880481</pub-id></element-citation></ref><ref id="B50-ijms-18-02406"><label>50.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schaffer</surname><given-names>A.</given-names></name><name><surname>Zuker</surname><given-names>P.</given-names></name><name><surname>Levitt</surname><given-names>A.</given-names></name></person-group><article-title>Randomized, double-blind pilot trial comparing lamotrigine versus citalopram for the treatment of bipolar depression</article-title><source>J. Affect. Disord.</source><year>2006</year><volume>96</volume><fpage>95</fpage><lpage>99</lpage><pub-id pub-id-type="doi">10.1016/j.jad.2006.05.023</pub-id><?supplied-pmid 16820213?><pub-id pub-id-type="pmid">16820213</pub-id></element-citation></ref><ref id="B51-ijms-18-02406"><label>51.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Amsterdam</surname><given-names>J.</given-names></name></person-group><article-title>Efficacy and safety of venlafaxine in the treatment of bipolar II major depressive episode</article-title><source>J. Clin. Psychopharmacol.</source><year>1998</year><volume>18</volume><fpage>414</fpage><lpage>417</lpage><pub-id pub-id-type="doi">10.1097/00004714-199810000-00010</pub-id><?supplied-pmid 9790160?><pub-id pub-id-type="pmid">9790160</pub-id></element-citation></ref><ref id="B52-ijms-18-02406"><label>52.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Amsterdam</surname><given-names>J.D.</given-names></name><name><surname>Garcia-Espana</surname><given-names>F.</given-names></name></person-group><article-title>Venlafaxine monotherapy in women with bipolar II and unipolar major depression</article-title><source>J. Affect. Disord.</source><year>2000</year><volume>59</volume><fpage>225</fpage><lpage>229</lpage><pub-id pub-id-type="doi">10.1016/S0165-0327(99)00149-4</pub-id><pub-id pub-id-type="pmid">10854639</pub-id></element-citation></ref><ref id="B53-ijms-18-02406"><label>53.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Amsterdam</surname><given-names>J.D.</given-names></name><name><surname>Lorenzo-Luaces</surname><given-names>L.</given-names></name><name><surname>Soeller</surname><given-names>I.</given-names></name><name><surname>Li</surname><given-names>S.Q.</given-names></name><name><surname>Mao</surname><given-names>J.J.</given-names></name><name><surname>DeRubeis</surname><given-names>R.J.</given-names></name></person-group><article-title>Short-term venlafaxine v. lithium monotherapy for bipolar type II major depressive episodes: Effectiveness and mood conversion rate</article-title><source>Br. J. Psychiatry</source><year>2016</year><volume>208</volume><fpage>359</fpage><lpage>365</lpage><pub-id pub-id-type="doi">10.1192/bjp.bp.115.169375</pub-id><?supplied-pmid 26892848?><pub-id pub-id-type="pmid">26892848</pub-id></element-citation></ref><ref id="B54-ijms-18-02406"><label>54.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sachs</surname><given-names>G.S.</given-names></name><name><surname>Lafer</surname><given-names>B.</given-names></name><name><surname>Stoll</surname><given-names>A.L.</given-names></name><name><surname>Banov</surname><given-names>M.</given-names></name><name><surname>Thibault</surname><given-names>A.B.</given-names></name><name><surname>Tohen</surname><given-names>M.</given-names></name><name><surname>Rosenbaum</surname><given-names>J.F.</given-names></name></person-group><article-title>A double-blind trial of bupropion versus desipramine for bipolar depression</article-title><source>J. Clin. Psychiatry</source><year>1994</year><volume>55</volume><fpage>391</fpage><lpage>393</lpage><?supplied-pmid 7929019?><pub-id pub-id-type="pmid">7929019</pub-id></element-citation></ref><ref id="B55-ijms-18-02406"><label>55.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Grossman</surname><given-names>F.</given-names></name><name><surname>Potter</surname><given-names>W.Z.</given-names></name><name><surname>Brown</surname><given-names>E.A.</given-names></name><name><surname>Maislin</surname><given-names>G.</given-names></name></person-group><article-title>A double-blind study comparing idazoxan and bupropion in bipolar depressed patients</article-title><source>J. Affect. Disord.</source><year>1999</year><volume>56</volume><fpage>237</fpage><lpage>243</lpage><pub-id pub-id-type="doi">10.1016/S0165-0327(99)00041-5</pub-id><pub-id pub-id-type="pmid">10701483</pub-id></element-citation></ref><ref id="B56-ijms-18-02406"><label>56.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gijsman</surname><given-names>H.J.</given-names></name><name><surname>Geddes</surname><given-names>J.R.</given-names></name><name><surname>Rendell</surname><given-names>J.M.</given-names></name><name><surname>Nolen</surname><given-names>W.A.</given-names></name><name><surname>Goodwin</surname><given-names>G.M.</given-names></name></person-group><article-title>Antidepressants for bipolar depression: A systematic review of randomized, controlled trials</article-title><source>Am. J. Psychiatry</source><year>2004</year><volume>161</volume><fpage>1537</fpage><lpage>1547</lpage><pub-id pub-id-type="doi">10.1176/appi.ajp.161.9.1537</pub-id><?supplied-pmid 15337640?><pub-id pub-id-type="pmid">15337640</pub-id></element-citation></ref><ref id="B57-ijms-18-02406"><label>57.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Salvi</surname><given-names>V.</given-names></name><name><surname>Fagiolini</surname><given-names>A.</given-names></name><name><surname>Swartz</surname><given-names>H.A.</given-names></name><name><surname>Maina</surname><given-names>G.</given-names></name><name><surname>Frank</surname><given-names>E.</given-names></name></person-group><article-title>The use of antidepressants in bipolar disorder</article-title><source>J. Clin. Psychiatry</source><year>2008</year><volume>69</volume><fpage>1307</fpage><lpage>1318</lpage><pub-id pub-id-type="doi">10.4088/JCP.v69n0816</pub-id><?supplied-pmid 18681751?><pub-id pub-id-type="pmid">18681751</pub-id></element-citation></ref><ref id="B58-ijms-18-02406"><label>58.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ghaemi</surname><given-names>S.N.</given-names></name></person-group><article-title>Treatment of rapid-cycling bipolar disorder: Are antidepressants mood destabilizers?</article-title><source>Am. J. Psychiatry</source><year>2008</year><volume>165</volume><fpage>300</fpage><lpage>302</lpage><pub-id pub-id-type="doi">10.1176/appi.ajp.2007.07121931</pub-id><?supplied-pmid 18316425?><pub-id pub-id-type="pmid">18316425</pub-id></element-citation></ref><ref id="B59-ijms-18-02406"><label>59.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lorenzo-Luaces</surname><given-names>L.</given-names></name><name><surname>Amsterdam</surname><given-names>J.D.</given-names></name><name><surname>Soeller</surname><given-names>I.</given-names></name><name><surname>DeRubeis</surname><given-names>R.J.</given-names></name></person-group><article-title>Rapid versus non-rapid cycling bipolar II depression: Response to venlafaxine and lithium and hypomanic risk</article-title><source>Acta Psychiatr. Scand.</source><year>2016</year><volume>133</volume><fpage>459</fpage><lpage>469</lpage><pub-id pub-id-type="doi">10.1111/acps.12557</pub-id><?supplied-pmid 26803764?><pub-id pub-id-type="pmid">26803764</pub-id></element-citation></ref><ref id="B60-ijms-18-02406"><label>60.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pacchiarotti</surname><given-names>I.</given-names></name><name><surname>Valent&#x000ed;</surname><given-names>M.</given-names></name><name><surname>Colom</surname><given-names>F.</given-names></name><name><surname>Rosa</surname><given-names>A.R.</given-names></name><name><surname>Nivoli</surname><given-names>A.M.</given-names></name><name><surname>Murru</surname><given-names>A.</given-names></name><name><surname>S&#x000e1;nchez-Moreno</surname><given-names>J.</given-names></name><name><surname>Vieta</surname><given-names>E.</given-names></name></person-group><article-title>Differential outcome of bipolar patients receiving antidepressant monotherapy versus combination with an antimanic drug</article-title><source>J. Affect. Disord.</source><year>2011</year><volume>129</volume><fpage>321</fpage><lpage>326</lpage><pub-id pub-id-type="doi">10.1016/j.jad.2010.07.036</pub-id><?supplied-pmid 20817267?><pub-id pub-id-type="pmid">20817267</pub-id></element-citation></ref><ref id="B61-ijms-18-02406"><label>61.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Undurraga</surname><given-names>J.</given-names></name><name><surname>Baldessarini</surname><given-names>R.J.</given-names></name><name><surname>Valenti</surname><given-names>M.</given-names></name><name><surname>Pacchiarotti</surname><given-names>I.</given-names></name><name><surname>Vieta</surname><given-names>E.</given-names></name></person-group><article-title>Suicidal risk factors in bipolar I and II disorder patients</article-title><source>J. Clin. Psychiatry</source><year>2012</year><volume>73</volume><fpage>778</fpage><lpage>782</lpage><pub-id pub-id-type="doi">10.4088/JCP.11m07041</pub-id><?supplied-pmid 22225677?><pub-id pub-id-type="pmid">22225677</pub-id></element-citation></ref><ref id="B62-ijms-18-02406"><label>62.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Leon</surname><given-names>A.C.</given-names></name><name><surname>Fiedorowicz</surname><given-names>J.G.</given-names></name><name><surname>Solomonon</surname><given-names>D.A.</given-names></name><name><surname>Li</surname><given-names>C.</given-names></name><name><surname>Coryell</surname><given-names>W.H.</given-names></name><name><surname>Endicott</surname><given-names>J.</given-names></name><name><surname>Fawcett</surname><given-names>J.</given-names></name><name><surname>Keller</surname><given-names>M.B.</given-names></name></person-group><article-title>Risk of suicidal behavior with antidepressants in bipolar and unipolar disorders</article-title><source>J. Clin. Psychiatry</source><year>2014</year><volume>75</volume><fpage>720</fpage><pub-id pub-id-type="doi">10.4088/JCP.13m08744</pub-id><?supplied-pmid 25093469?><pub-id pub-id-type="pmid">25093469</pub-id></element-citation></ref><ref id="B63-ijms-18-02406"><label>63.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bauer</surname><given-names>M.S.</given-names></name><name><surname>Wisniewski</surname><given-names>S.R.</given-names></name><name><surname>Marangell</surname><given-names>L.B.</given-names></name><name><surname>Chessick</surname><given-names>C.A.</given-names></name><name><surname>Allen</surname><given-names>M.H.</given-names></name><name><surname>Dennehy</surname><given-names>E.B.</given-names></name><name><surname>Miklowitz</surname><given-names>D.J.</given-names></name><name><surname>Thase</surname><given-names>M.E.</given-names></name><name><surname>Sachs</surname><given-names>G.S.</given-names></name></person-group><article-title>Are antidepressants associated with new-onset suicidality in bipolar disorder? A prospective study of participants in the Systematic Treatment Enhancement Program for Bipolar Disorder (STEP-BD)</article-title><source>J. Clin. Psychiatry</source><year>2006</year><volume>67</volume><fpage>48</fpage><lpage>55</lpage><pub-id pub-id-type="doi">10.4088/JCP.v67n0108</pub-id><?supplied-pmid 16426088?><pub-id pub-id-type="pmid">16426088</pub-id></element-citation></ref><ref id="B64-ijms-18-02406"><label>64.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tondo</surname><given-names>L.</given-names></name><name><surname>Lepri</surname><given-names>B.</given-names></name><name><surname>Baldessarini</surname><given-names>R.J.</given-names></name></person-group><article-title>Suicidal status during antidepressant treatment in 789 Sardinian patients with major affective disorder</article-title><source>Acta Psychiatr. Scand.</source><year>2008</year><volume>118</volume><fpage>106</fpage><lpage>115</lpage><pub-id pub-id-type="doi">10.1111/j.1600-0447.2008.01178.x</pub-id><?supplied-pmid 18397362?><pub-id pub-id-type="pmid">18397362</pub-id></element-citation></ref><ref id="B65-ijms-18-02406"><label>65.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Koukopoulos</surname><given-names>A.</given-names></name><name><surname>Sani</surname><given-names>G.</given-names></name><name><surname>Koukopoulos</surname><given-names>A.E.</given-names></name><name><surname>Manfredi</surname><given-names>G.</given-names></name><name><surname>Pacchiarotti</surname><given-names>I.</given-names></name><name><surname>Girardi</surname><given-names>P.</given-names></name></person-group><article-title>Melancholia agitata and mixed depression</article-title><source>Acta Psychiatr. Scand.</source><year>2007</year><volume>115</volume><fpage>50</fpage><lpage>57</lpage><pub-id pub-id-type="doi">10.1111/j.1600-0447.2007.00963.x</pub-id><?supplied-pmid 17280571?><pub-id pub-id-type="pmid">17280571</pub-id></element-citation></ref><ref id="B66-ijms-18-02406"><label>66.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rihmer</surname><given-names>Z.</given-names></name><name><surname>Gonda</surname><given-names>X.</given-names></name></person-group><article-title>Antidepressant-resistant depression and antidepressant-associated suicidal behaviour: The role of underlying bipolarity</article-title><source>Depress. Res. Treat.</source><year>2011</year><volume>2011</volume><fpage>906462</fpage><pub-id pub-id-type="doi">10.1155/2011/906462</pub-id><?supplied-pmid 21603142?><pub-id pub-id-type="pmid">21603142</pub-id></element-citation></ref><ref id="B67-ijms-18-02406"><label>67.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Goodwin</surname><given-names>G.M.</given-names></name></person-group><article-title>Consensus Group of the British Association for Psychopharmacology. Evidence-based guidelines for treating bipolar disorder: Revised second edition&#x02014;recommendations from the British Association for Psychopharmacology</article-title><source>J. Psychopharmacol.</source><year>2009</year><volume>23</volume><fpage>346</fpage><lpage>388</lpage><pub-id pub-id-type="doi">10.1177/0269881109102919</pub-id><?supplied-pmid 19329543?><pub-id pub-id-type="pmid">19329543</pub-id></element-citation></ref><ref id="B68-ijms-18-02406"><label>68.</label><element-citation publication-type="book"><person-group person-group-type="author"><collab>National Collaborating Centre for Mental Health</collab></person-group><source>Bipolar Disorder: The Assessment and Management of Bipolar Disorder in Adults, Children and Young People in Primary and Secondary Care</source><publisher-name>The British Psychological Society &#x00026; The Royal College of Psychiatrists</publisher-name><publisher-loc>Leicester, UK</publisher-loc><year>2014</year></element-citation></ref><ref id="B69-ijms-18-02406"><label>69.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tada</surname><given-names>M.</given-names></name><name><surname>Uchida</surname><given-names>H.</given-names></name><name><surname>Mizushima</surname><given-names>J.</given-names></name><name><surname>Suzuki</surname><given-names>T.</given-names></name><name><surname>Mimura</surname><given-names>M.</given-names></name><name><surname>Nio</surname><given-names>S.</given-names></name></person-group><article-title>Antidepressant dose and treatment response in bipolar depression: Reanalysis of the Systematic Treatment Enhancement Program for Bipolar Disorder (STEP-BD) data</article-title><source>J. Psychiatr. Res.</source><year>2015</year><volume>68</volume><fpage>151</fpage><lpage>156</lpage><pub-id pub-id-type="doi">10.1016/j.jpsychires.2015.06.015</pub-id><?supplied-pmid 26228414?><pub-id pub-id-type="pmid">26228414</pub-id></element-citation></ref><ref id="B70-ijms-18-02406"><label>70.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Goldberg</surname><given-names>J.F.</given-names></name><name><surname>Perlis</surname><given-names>R.H.</given-names></name><name><surname>Ghaemi</surname><given-names>S.N.</given-names></name><name><surname>Calabrese</surname><given-names>J.R.</given-names></name><name><surname>Bowden</surname><given-names>C.L.</given-names></name><name><surname>Wisniewski</surname><given-names>S.</given-names></name><name><surname>Miklowitz</surname><given-names>D.J.</given-names></name><name><surname>Sachs</surname><given-names>G.S.</given-names></name><name><surname>Thase</surname><given-names>M.E.</given-names></name></person-group><article-title>Adjunctive antidepressant use and symptomatic recovery among bipolar depressed patients with concomitant manic symptoms: Findings from the STEP-BD</article-title><source>Am. J. Psychiatry</source><year>2007</year><volume>164</volume><fpage>1348</fpage><lpage>1355</lpage><pub-id pub-id-type="doi">10.1176/appi.ajp.2007.05122032</pub-id><?supplied-pmid 17728419?><pub-id pub-id-type="pmid">17728419</pub-id></element-citation></ref><ref id="B71-ijms-18-02406"><label>71.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Amsterdam</surname><given-names>J.D.</given-names></name><name><surname>Shults</surname><given-names>J.</given-names></name></person-group><article-title>Efficacy and safety of long-term fluoxetine versus lithium monotherapy of bipolar II disorder: A randomized, double-blind, placebo-substitution study</article-title><source>Am. J. Psychiatry</source><year>2010</year><volume>167</volume><fpage>792</fpage><lpage>800</lpage><pub-id pub-id-type="doi">10.1176/appi.ajp.2009.09020284</pub-id><?supplied-pmid 20360317?><pub-id pub-id-type="pmid">20360317</pub-id></element-citation></ref><ref id="B72-ijms-18-02406"><label>72.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ghaemi</surname><given-names>S.N.</given-names></name><name><surname>Ostacher</surname><given-names>M.M.</given-names></name><name><surname>El-Mallakh</surname><given-names>R.S.</given-names></name><name><surname>Borrelli</surname><given-names>D.</given-names></name><name><surname>Baldassano</surname><given-names>C.F.</given-names></name><name><surname>Kelley</surname><given-names>M.E.</given-names></name><name><surname>Filkowski</surname><given-names>M.M.</given-names></name><name><surname>Hennen</surname><given-names>J.</given-names></name><name><surname>Sachs</surname><given-names>G.S.</given-names></name><name><surname>Goodwin</surname><given-names>F.K.</given-names></name><etal/></person-group><article-title>Antidepressant discontinuation in bipolar depression: A Systematic Treatment Enhancement Program for Bipolar Disorder (STEP-BD) randomized clinical trial of long-term effectiveness and safety</article-title><source>J. Clin. Psychiatry</source><year>2010</year><volume>71</volume><fpage>372</fpage><lpage>380</lpage><pub-id pub-id-type="doi">10.4088/JCP.08m04909gre</pub-id><?supplied-pmid 20409444?><pub-id pub-id-type="pmid">20409444</pub-id></element-citation></ref><ref id="B73-ijms-18-02406"><label>73.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zornberg</surname><given-names>G.L.</given-names></name><name><surname>Pope</surname><given-names>H.G.</given-names><suffix>Jr.</suffix></name></person-group><article-title>Treatment of depression in bipolar disorder: New directions for research</article-title><source>J. Clin. Psychopharmacol.</source><year>1993</year><volume>13</volume><fpage>397</fpage><lpage>408</lpage><pub-id pub-id-type="doi">10.1097/00004714-199312000-00005</pub-id><?supplied-pmid 8120153?><pub-id pub-id-type="pmid">8120153</pub-id></element-citation></ref><ref id="B74-ijms-18-02406"><label>74.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fountoulakis</surname><given-names>K.N.</given-names></name><name><surname>Grunze</surname><given-names>H.</given-names></name><name><surname>Panagiotidis</surname><given-names>P.</given-names></name><name><surname>Kaprinis</surname><given-names>G.</given-names></name></person-group><article-title>Treatment of bipolar depression: An update</article-title><source>J. Affect. Disord.</source><year>2008</year><volume>109</volume><fpage>21</fpage><lpage>34</lpage><pub-id pub-id-type="doi">10.1016/j.jad.2007.10.016</pub-id><?supplied-pmid 18037498?><pub-id pub-id-type="pmid">18037498</pub-id></element-citation></ref><ref id="B75-ijms-18-02406"><label>75.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cipriani</surname><given-names>A.</given-names></name><name><surname>Hawton</surname><given-names>K.</given-names></name><name><surname>Stockton</surname><given-names>S.</given-names></name><name><surname>Geddes</surname><given-names>J.R.</given-names></name></person-group><article-title>Lithium in the prevention of suicide in mood disorders: Updated systematic review and meta-analysis</article-title><source>BMJ</source><year>2013</year><volume>346</volume><fpage>f3646</fpage><pub-id pub-id-type="doi">10.1136/bmj.f3646</pub-id><?supplied-pmid 23814104?><pub-id pub-id-type="pmid">23814104</pub-id></element-citation></ref><ref id="B76-ijms-18-02406"><label>76.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Calabrese</surname><given-names>J.R.</given-names></name><name><surname>Vieta</surname><given-names>E.</given-names></name><name><surname>Shelton</surname><given-names>M.D.</given-names></name></person-group><article-title>Latest maintenance data on lamotrigine in bipolar disorder</article-title><source>Eur. Neuropsychopharmacol.</source><year>2003</year><volume>13</volume><issue>Suppl. 2</issue><fpage>S57</fpage><lpage>S66</lpage><pub-id pub-id-type="doi">10.1016/S0924-977X(03)00079-8</pub-id><pub-id pub-id-type="pmid">12957721</pub-id></element-citation></ref><ref id="B77-ijms-18-02406"><label>77.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Goodwin</surname><given-names>G.M.</given-names></name><name><surname>Bowden</surname><given-names>C.L.</given-names></name><name><surname>Calabrese</surname><given-names>J.R.</given-names></name><name><surname>Grunze</surname><given-names>H.</given-names></name><name><surname>Kasper</surname><given-names>S.</given-names></name><name><surname>White</surname><given-names>R.</given-names></name><name><surname>Greene</surname><given-names>P.</given-names></name><name><surname>Leadbetter</surname><given-names>R.</given-names></name></person-group><article-title>A pooled analysis of 2 placebo-controlled 18-month trials of lamotrigine and lithium maintenance in bipolar I disorder</article-title><source>J. Clin. Psychiatry</source><year>2004</year><volume>65</volume><fpage>432</fpage><lpage>441</lpage><pub-id pub-id-type="doi">10.4088/JCP.v65n0321</pub-id><?supplied-pmid 15096085?><pub-id pub-id-type="pmid">15096085</pub-id></element-citation></ref><ref id="B78-ijms-18-02406"><label>78.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Crossley</surname><given-names>N.A.</given-names></name><name><surname>Bauer</surname><given-names>M.</given-names></name></person-group><article-title>Acceleration and augmentation of antidepressants with lithium for depressive disorders: Two meta-analyses of randomized, placebo-controlled trials</article-title><source>J. Clin. Psychiatry</source><year>2007</year><volume>68</volume><fpage>935</fpage><lpage>940</lpage><pub-id pub-id-type="doi">10.4088/JCP.v68n0617</pub-id><?supplied-pmid 17592920?><pub-id pub-id-type="pmid">17592920</pub-id></element-citation></ref><ref id="B79-ijms-18-02406"><label>79.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Inoue</surname><given-names>T.</given-names></name><name><surname>Abekawa</surname><given-names>T.</given-names></name><name><surname>Nakagawa</surname><given-names>S.</given-names></name><name><surname>Suzuki</surname><given-names>K.</given-names></name><name><surname>Tanaka</surname><given-names>T.</given-names></name><name><surname>Kitaichi</surname><given-names>Y.</given-names></name><name><surname>Boku</surname><given-names>S.</given-names></name><name><surname>Nakato</surname><given-names>Y.</given-names></name><name><surname>Toda</surname><given-names>H.</given-names></name><name><surname>Koyama</surname><given-names>T.</given-names></name></person-group><article-title>Long-term naturalistic follow-up of lithium augmentation: Relevance to bipolarity</article-title><source>J. Affect. Disord.</source><year>2011</year><volume>129</volume><fpage>64</fpage><lpage>67</lpage><pub-id pub-id-type="doi">10.1016/j.jad.2010.08.022</pub-id><?supplied-pmid 20837361?><pub-id pub-id-type="pmid">20837361</pub-id></element-citation></ref><ref id="B80-ijms-18-02406"><label>80.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Suppes</surname><given-names>T.</given-names></name><name><surname>Baldessarini</surname><given-names>R.J.</given-names></name><name><surname>Faedda</surname><given-names>G.L.</given-names></name><name><surname>Tohen</surname><given-names>M.</given-names></name></person-group><article-title>Risk of recurrence following discontinuation of lithium treatment in bipolar disorder</article-title><source>Arch. Gen. Psychiatry</source><year>1991</year><volume>48</volume><fpage>1082</fpage><lpage>1088</lpage><pub-id pub-id-type="doi">10.1001/archpsyc.1991.01810360046007</pub-id><?supplied-pmid 1845226?><pub-id pub-id-type="pmid">1845226</pub-id></element-citation></ref><ref id="B81-ijms-18-02406"><label>81.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Grunze</surname><given-names>H.</given-names></name></person-group><article-title>Lithium in the acute treatment of bipolar disorders&#x02014;A stocktaking</article-title><source>Eur. Arch. Psychiatry Clin. Neurosci.</source><year>2003</year><volume>253</volume><fpage>115</fpage><lpage>119</lpage><pub-id pub-id-type="doi">10.1007/s00406-003-0427-4</pub-id><?supplied-pmid 12904974?><pub-id pub-id-type="pmid">12904974</pub-id></element-citation></ref><ref id="B82-ijms-18-02406"><label>82.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Van der Loos</surname><given-names>M.L.</given-names></name><name><surname>Mulder</surname><given-names>P.</given-names></name><name><surname>Hartong</surname><given-names>E.G.</given-names></name><name><surname>Blom</surname><given-names>M.B.</given-names></name><name><surname>Vergouwen</surname><given-names>A.C.</given-names></name><name><surname>van Noorden</surname><given-names>M.S.</given-names></name><name><surname>Timmermans</surname><given-names>M.A.</given-names></name><name><surname>Vieta</surname><given-names>E.</given-names></name><name><surname>Nolen</surname><given-names>W.A.</given-names></name></person-group><article-title>Long-term outcome of bipolar depressed patients receiving lamotrigine as add-on to lithium with the possibility of the addition of paroxetine in nonresponders: A randomized, placebo-controlled trial with a novel design</article-title><source>Bipolar Disord.</source><year>2011</year><volume>13</volume><fpage>111</fpage><lpage>117</lpage><pub-id pub-id-type="doi">10.1111/j.1399-5618.2011.00887.x</pub-id><?supplied-pmid 21320258?><pub-id pub-id-type="pmid">21320258</pub-id></element-citation></ref><ref id="B83-ijms-18-02406"><label>83.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Suppes</surname><given-names>T.</given-names></name><name><surname>Marangell</surname><given-names>L.B.</given-names></name><name><surname>Bernstein</surname><given-names>I.H.</given-names></name><name><surname>Kelly</surname><given-names>D.I.</given-names></name><name><surname>Fischer</surname><given-names>E.G.</given-names></name><name><surname>Zboyan</surname><given-names>H.A.</given-names></name><name><surname>Snow</surname><given-names>D.E.</given-names></name><name><surname>Martinez</surname><given-names>M.</given-names></name><name><surname>Al Jurdi</surname><given-names>R.</given-names></name><name><surname>Shivakumar</surname><given-names>G.</given-names></name><etal/></person-group><article-title>A single blind comparison of lithium and lamotrigine for the treatment of bipolar II depression</article-title><source>J. Affect. Disord.</source><year>2008</year><volume>111</volume><fpage>334</fpage><lpage>343</lpage><pub-id pub-id-type="doi">10.1016/j.jad.2008.02.004</pub-id><?supplied-pmid 18358540?><pub-id pub-id-type="pmid">18358540</pub-id></element-citation></ref><ref id="B84-ijms-18-02406"><label>84.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Calabrese</surname><given-names>J.R.</given-names></name><name><surname>Huffman</surname><given-names>R.F.</given-names></name><name><surname>White</surname><given-names>R.L.</given-names></name><name><surname>Edwards</surname><given-names>S.</given-names></name><name><surname>Thompson</surname><given-names>T.R.</given-names></name><name><surname>Ascher</surname><given-names>J.A.</given-names></name><name><surname>Monaghan</surname><given-names>E.T.</given-names></name><name><surname>Leadbetter</surname><given-names>R.A.</given-names></name></person-group><article-title>Lamotrigine in the acute treatment of bipolar depression: Results of five double-blind, placebo-controlled clinical trials</article-title><source>Bipolar Disord.</source><year>2008</year><volume>10</volume><fpage>323</fpage><lpage>333</lpage><pub-id pub-id-type="doi">10.1111/j.1399-5618.2007.00500.x</pub-id><?supplied-pmid 18271912?><pub-id pub-id-type="pmid">18271912</pub-id></element-citation></ref><ref id="B85-ijms-18-02406"><label>85.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Goodwin</surname><given-names>G.M.</given-names></name><name><surname>Haddad</surname><given-names>P.M.</given-names></name><name><surname>Ferrier</surname><given-names>I.N.</given-names></name><name><surname>Aronson</surname><given-names>J.K.</given-names></name><name><surname>Barnes</surname><given-names>T.</given-names></name><name><surname>Cipriani</surname><given-names>A.</given-names></name><name><surname>Coghill</surname><given-names>D.R.</given-names></name><name><surname>Fazel</surname><given-names>S.</given-names></name><name><surname>Geddes</surname><given-names>J.R.</given-names></name><name><surname>Grunze</surname><given-names>H.</given-names></name><etal/></person-group><article-title>Evidence-based guidelines for treating bipolar disorder: Revised third edition recommendations from the British Association for Psychopharmacology</article-title><source>J. Psychopharmacol.</source><year>2016</year><volume>30</volume><fpage>495</fpage><lpage>553</lpage><pub-id pub-id-type="doi">10.1177/0269881116636545</pub-id><?supplied-pmid 26979387?><pub-id pub-id-type="pmid">26979387</pub-id></element-citation></ref><ref id="B86-ijms-18-02406"><label>86.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fountoulakis</surname><given-names>K.N.</given-names></name><name><surname>Kasper</surname><given-names>S.</given-names></name><name><surname>Andreassen</surname><given-names>O.</given-names></name><name><surname>Blier</surname><given-names>P.</given-names></name><name><surname>Okasha</surname><given-names>A.</given-names></name><name><surname>Severus</surname><given-names>E.</given-names></name><name><surname>Versiani</surname><given-names>M.</given-names></name><name><surname>Tandon</surname><given-names>R.</given-names></name><name><surname>Moller</surname><given-names>H.J.</given-names></name><name><surname>Vieta</surname><given-names>E.</given-names></name></person-group><article-title>Efficacy of pharmacotherapy in bipolar disorder: A report by the WPA section on pharmacopsychiatry</article-title><source>Eur. Arch. Psychiatry Clin. Neurosci.</source><year>2012</year><volume>262</volume><issue>Suppl. 1</issue><fpage>1</fpage><lpage>48</lpage><pub-id pub-id-type="doi">10.1007/s00406-012-0323-x</pub-id><?supplied-pmid 22622948?><pub-id pub-id-type="pmid">22622948</pub-id></element-citation></ref><ref id="B87-ijms-18-02406"><label>87.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Geddes</surname><given-names>J.R.</given-names></name><name><surname>Calabrese</surname><given-names>J.R.</given-names></name><name><surname>Goodwin</surname><given-names>G.M.</given-names></name></person-group><article-title>Lamotrigine for treatment of bipolar depression: Independent meta-analysis and meta-regression of individual patient data from five randomised trials</article-title><source>Br. J. Psychiatry</source><year>2009</year><volume>194</volume><fpage>4</fpage><lpage>9</lpage><pub-id pub-id-type="doi">10.1192/bjp.bp.107.048504</pub-id><?supplied-pmid 19118318?><pub-id pub-id-type="pmid">19118318</pub-id></element-citation></ref><ref id="B88-ijms-18-02406"><label>88.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bond</surname><given-names>D.J.</given-names></name><name><surname>Lam</surname><given-names>R.W.</given-names></name><name><surname>Yatham</surname><given-names>L.N.</given-names></name></person-group><article-title>Divalproex sodium versus placebo in the treatment of acute bipolar depression: A systematic review and meta-analysis</article-title><source>J. Affect. Disord.</source><year>2010</year><volume>124</volume><fpage>228</fpage><lpage>234</lpage><pub-id pub-id-type="doi">10.1016/j.jad.2009.11.008</pub-id><?supplied-pmid 20044142?><pub-id pub-id-type="pmid">20044142</pub-id></element-citation></ref><ref id="B89-ijms-18-02406"><label>89.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Selle</surname><given-names>V.</given-names></name><name><surname>Schalkwijk</surname><given-names>S.</given-names></name><name><surname>Vazquez</surname><given-names>G.H.</given-names></name><name><surname>Baldessarini</surname><given-names>R.J.</given-names></name></person-group><article-title>Treatments for acute bipolar depression: Meta-analyses of placebo-controlled, monotherapy trials of anticonvulsants, lithium and antipsychotics</article-title><source>Pharmacopsychiatry</source><year>2014</year><volume>47</volume><fpage>43</fpage><lpage>52</lpage><pub-id pub-id-type="doi">10.1055/s-0033-1363258</pub-id><?supplied-pmid 24549862?><pub-id pub-id-type="pmid">24549862</pub-id></element-citation></ref><ref id="B90-ijms-18-02406"><label>90.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gyulai</surname><given-names>L.</given-names></name><name><surname>Bowden</surname><given-names>C.L.</given-names></name><name><surname>McElroy</surname><given-names>S.L.</given-names></name><name><surname>Calabrese</surname><given-names>J.R.</given-names></name><name><surname>Petty</surname><given-names>F.</given-names></name><name><surname>Swann</surname><given-names>A.C.</given-names></name><name><surname>Chou</surname><given-names>J.C.</given-names></name><name><surname>Wassef</surname><given-names>A.</given-names></name><name><surname>Risch</surname><given-names>C.S.</given-names></name><name><surname>Hirschfeld</surname><given-names>R.M.</given-names></name><etal/></person-group><article-title>Maintenance efficacy of divalproex in the prevention of bipolar depression</article-title><source>Neuropsychopharmacology</source><year>2003</year><volume>28</volume><fpage>1374</fpage><lpage>1382</lpage><pub-id pub-id-type="doi">10.1038/sj.npp.1300190</pub-id><?supplied-pmid 12784116?><pub-id pub-id-type="pmid">12784116</pub-id></element-citation></ref><ref id="B91-ijms-18-02406"><label>91.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Solomon</surname><given-names>D.A.</given-names></name><name><surname>Ryan</surname><given-names>C.E.</given-names></name><name><surname>Keitner</surname><given-names>G.I.</given-names></name><name><surname>Miller</surname><given-names>I.W.</given-names></name><name><surname>Shea</surname><given-names>M.T.</given-names></name><name><surname>Kazim</surname><given-names>A.</given-names></name><name><surname>Keller</surname><given-names>M.B.</given-names></name></person-group><article-title>A pilot study of lithium carbonate plus divalproex sodium for the continuation and maintenance treatment of patients with bipolar I disorder</article-title><source>J. Clin. Psychiatry</source><year>1997</year><volume>58</volume><fpage>95</fpage><lpage>99</lpage><pub-id pub-id-type="doi">10.4088/JCP.v58n0301</pub-id><?supplied-pmid 9108809?><pub-id pub-id-type="pmid">9108809</pub-id></element-citation></ref><ref id="B92-ijms-18-02406"><label>92.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Coxhead</surname><given-names>N.</given-names></name><name><surname>Silverstone</surname><given-names>T.</given-names></name><name><surname>Cookson</surname><given-names>J.</given-names></name></person-group><article-title>Carbamazepine versus lithium in the prophylaxis of bipolar affective disorder</article-title><source>Acta Psychiatr. Scand.</source><year>1992</year><volume>85</volume><fpage>114</fpage><lpage>118</lpage><pub-id pub-id-type="doi">10.1111/j.1600-0447.1992.tb01453.x</pub-id><?supplied-pmid 1543034?><pub-id pub-id-type="pmid">1543034</pub-id></element-citation></ref><ref id="B93-ijms-18-02406"><label>93.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Greil</surname><given-names>W.</given-names></name><name><surname>Ludwig-Mayerhofer</surname><given-names>W.</given-names></name><name><surname>Erazo</surname><given-names>N.</given-names></name><name><surname>Schochlin</surname><given-names>C.</given-names></name><name><surname>Schmidt</surname><given-names>S.</given-names></name><name><surname>Engel</surname><given-names>R.R.</given-names></name><name><surname>Czernik</surname><given-names>A.</given-names></name><name><surname>Giedke</surname><given-names>H.</given-names></name><name><surname>Muller-Oerlinghausen</surname><given-names>B.</given-names></name><name><surname>Osterheider</surname><given-names>M.</given-names></name><etal/></person-group><article-title>Lithium versus carbamazepine in the maintenance treatment of bipolar disorders&#x02014;A randomised study</article-title><source>J. Affect. Disord.</source><year>1997</year><volume>43</volume><fpage>151</fpage><lpage>161</lpage><pub-id pub-id-type="doi">10.1016/S0165-0327(96)01427-9</pub-id><pub-id pub-id-type="pmid">9165384</pub-id></element-citation></ref><ref id="B94-ijms-18-02406"><label>94.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Greil</surname><given-names>W.</given-names></name><name><surname>Kleindienst</surname><given-names>N.</given-names></name><name><surname>Erazo</surname><given-names>N.</given-names></name><name><surname>Muller-Oerlinghausen</surname><given-names>B.</given-names></name></person-group><article-title>Differential response to lithium and carbamazepine in the prophylaxis of bipolar disorder</article-title><source>J. Clin. Psychopharmacol.</source><year>1998</year><volume>18</volume><fpage>455</fpage><lpage>460</lpage><pub-id pub-id-type="doi">10.1097/00004714-199812000-00007</pub-id><?supplied-pmid 9864077?><pub-id pub-id-type="pmid">9864077</pub-id></element-citation></ref><ref id="B95-ijms-18-02406"><label>95.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hartong</surname><given-names>E.G.</given-names></name><name><surname>Moleman</surname><given-names>P.</given-names></name><name><surname>Hoogduin</surname><given-names>C.A.</given-names></name><name><surname>Broekman</surname><given-names>T.G.</given-names></name><name><surname>Nolen</surname><given-names>W.A.</given-names></name></person-group><article-title>Prophylactic efficacy of lithium versus carbamazepine in treatment-naive bipolar patients</article-title><source>J. Clin. Psychiatry</source><year>2003</year><volume>64</volume><fpage>144</fpage><lpage>151</lpage><pub-id pub-id-type="doi">10.4088/JCP.v64n0206</pub-id><?supplied-pmid 12633122?><pub-id pub-id-type="pmid">12633122</pub-id></element-citation></ref><ref id="B96-ijms-18-02406"><label>96.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Watkins</surname><given-names>S.E.</given-names></name><name><surname>Callender</surname><given-names>K.</given-names></name><name><surname>Thomas</surname><given-names>D.R.</given-names></name><name><surname>Tidmarsh</surname><given-names>S.F.</given-names></name><name><surname>Shaw</surname><given-names>D.</given-names></name></person-group><article-title>The effect of carbamazepine and lithium on remission from affective illness</article-title><source>Br. J. Psychiatry</source><year>1987</year><volume>150</volume><fpage>180</fpage><lpage>182</lpage><pub-id pub-id-type="doi">10.1192/bjp.150.2.180</pub-id><?supplied-pmid 3115347?><pub-id pub-id-type="pmid">3115347</pub-id></element-citation></ref><ref id="B97-ijms-18-02406"><label>97.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Denicoff</surname><given-names>K.D.</given-names></name><name><surname>Smith-Jackson</surname><given-names>E.E.</given-names></name><name><surname>Disney</surname><given-names>E.R.</given-names></name><name><surname>Ali</surname><given-names>S.O.</given-names></name><name><surname>Leverich</surname><given-names>G.S.</given-names></name><name><surname>Post</surname><given-names>R.M.</given-names></name></person-group><article-title>Comparative prophylactic efficacy of lithium, carbamazepine, and the combination in bipolar disorder</article-title><source>J. Clin. Psychiatry</source><year>1997</year><volume>58</volume><fpage>470</fpage><lpage>478</lpage><pub-id pub-id-type="doi">10.4088/JCP.v58n1102</pub-id><?supplied-pmid 9413412?><pub-id pub-id-type="pmid">9413412</pub-id></element-citation></ref><ref id="B98-ijms-18-02406"><label>98.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Grande</surname><given-names>I.</given-names></name><name><surname>Berk</surname><given-names>M.</given-names></name><name><surname>Birmaher</surname><given-names>B.</given-names></name><name><surname>Vieta</surname><given-names>E.</given-names></name></person-group><article-title>Bipolar disorder</article-title><source>Lancet</source><year>2016</year><volume>387</volume><fpage>1561</fpage><lpage>1572</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(15)00241-X</pub-id><pub-id pub-id-type="pmid">26388529</pub-id></element-citation></ref><ref id="B99-ijms-18-02406"><label>99.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sun</surname><given-names>N.</given-names></name><name><surname>Lei</surname><given-names>L.</given-names></name><name><surname>Wang</surname><given-names>Y.</given-names></name><name><surname>Yang</surname><given-names>C.</given-names></name><name><surname>Liu</surname><given-names>Z.</given-names></name><name><surname>Li</surname><given-names>X.</given-names></name><name><surname>Zhang</surname><given-names>K.</given-names></name></person-group><article-title>Preliminary comparison of plasma notch-associated microRNA-34b and -34c levels in drug naive, first episode depressed patients and healthy controls</article-title><source>J. Affect. Disord.</source><year>2016</year><volume>194</volume><fpage>109</fpage><lpage>114</lpage><pub-id pub-id-type="doi">10.1016/j.jad.2016.01.017</pub-id><?supplied-pmid 26807671?><pub-id pub-id-type="pmid">26807671</pub-id></element-citation></ref><ref id="B100-ijms-18-02406"><label>100.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Baudry</surname><given-names>A.</given-names></name><name><surname>Mouillet-Richard</surname><given-names>S.</given-names></name><name><surname>Schneider</surname><given-names>B.</given-names></name><name><surname>Launay</surname><given-names>J.-M.</given-names></name><name><surname>Kellermann</surname><given-names>O.</given-names></name></person-group><article-title>miR-16 targets the serotonin transporter: A new facet for adaptive responses to antidepressants</article-title><source>Science</source><year>2010</year><volume>329</volume><fpage>1537</fpage><lpage>1541</lpage><pub-id pub-id-type="doi">10.1126/science.1193692</pub-id><?supplied-pmid 20847275?><pub-id pub-id-type="pmid">20847275</pub-id></element-citation></ref><ref id="B101-ijms-18-02406"><label>101.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lopez</surname><given-names>J.P.</given-names></name><name><surname>Lim</surname><given-names>R.</given-names></name><name><surname>Cruceanu</surname><given-names>C.</given-names></name><name><surname>Crapper</surname><given-names>L.</given-names></name><name><surname>Fasano</surname><given-names>C.</given-names></name><name><surname>Labonte</surname><given-names>B.</given-names></name><name><surname>Maussion</surname><given-names>G.</given-names></name><name><surname>Yang</surname><given-names>J.P.</given-names></name><name><surname>Yerko</surname><given-names>V.</given-names></name><name><surname>Vigneault</surname><given-names>E.</given-names></name></person-group><article-title>miR-1202 is a primate-specific and brain-enriched microRNA involved in major depression and antidepressant treatment</article-title><source>Nat. Med.</source><year>2014</year><volume>20</volume><fpage>764</fpage><lpage>768</lpage><pub-id pub-id-type="doi">10.1038/nm.3582</pub-id><?supplied-pmid 24908571?><pub-id pub-id-type="pmid">24908571</pub-id></element-citation></ref><ref id="B102-ijms-18-02406"><label>102.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Blazquez</surname><given-names>A.</given-names></name><name><surname>Gasso</surname><given-names>P.</given-names></name><name><surname>Mas</surname><given-names>S.</given-names></name><name><surname>Plana</surname><given-names>M.T.</given-names></name><name><surname>Lafuente</surname><given-names>A.</given-names></name><name><surname>Lazaro</surname><given-names>L.</given-names></name></person-group><article-title>One-Year Follow-up of Children and Adolescents with Major Depressive Disorder: Relationship between Clinical Variables and Abcb1 Gene Polymorphisms</article-title><source>Pharmacopsychiatry</source><year>2016</year><volume>49</volume><fpage>248</fpage><lpage>253</lpage><pub-id pub-id-type="doi">10.1055/s-0042-108202</pub-id><?supplied-pmid 27309038?><pub-id pub-id-type="pmid">27309038</pub-id></element-citation></ref><ref id="B103-ijms-18-02406"><label>103.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Taranu</surname><given-names>A.</given-names></name><name><surname>Asmar</surname><given-names>K.E.</given-names></name><name><surname>Colle</surname><given-names>R.</given-names></name><name><surname>Ferreri</surname><given-names>F.</given-names></name><name><surname>Polosan</surname><given-names>M.</given-names></name><name><surname>David</surname><given-names>D.</given-names></name><name><surname>Becquemont</surname><given-names>L.</given-names></name><name><surname>Corruble</surname><given-names>E.</given-names></name><name><surname>Verstuyft</surname><given-names>C.</given-names></name></person-group><article-title>The Catechol-O-methyltransferase Val(108/158)Met Genetic Polymorphism cannot be Recommended as a Biomarker for the Prediction of Venlafaxine Efficacy in Patients Treated in Psychiatric Settings</article-title><source>Basic Clin. Pharmacol. Toxicol.</source><year>2017</year><volume>121</volume><fpage>435</fpage><lpage>441</lpage><pub-id pub-id-type="doi">10.1111/bcpt.12827</pub-id><?supplied-pmid 28627776?><pub-id pub-id-type="pmid">28627776</pub-id></element-citation></ref><ref id="B104-ijms-18-02406"><label>104.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Oedegaard</surname><given-names>K.J.</given-names></name><name><surname>Alda</surname><given-names>M.</given-names></name><name><surname>Anand</surname><given-names>A.</given-names></name><name><surname>Andreassen</surname><given-names>O.A.</given-names></name><name><surname>Balaraman</surname><given-names>Y.</given-names></name><name><surname>Berrettini</surname><given-names>W.H.</given-names></name><name><surname>Bhattacharjee</surname><given-names>A.</given-names></name><name><surname>Brennand</surname><given-names>K.J.</given-names></name><name><surname>Burdick</surname><given-names>K.E.</given-names></name><name><surname>Calabrese</surname><given-names>J.R.</given-names></name><etal/></person-group><article-title>The Pharmacogenomics of Bipolar Disorder study (PGBD): Identification of genes for lithium response in a prospective sample</article-title><source>BMC Psychiatry</source><year>2016</year><volume>16</volume><elocation-id>129</elocation-id><pub-id pub-id-type="doi">10.1186/s12888-016-0732-x</pub-id><?supplied-pmid 27150464?><pub-id pub-id-type="pmid">27150464</pub-id></element-citation></ref><ref id="B105-ijms-18-02406"><label>105.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mayberg</surname><given-names>H.S.</given-names></name><name><surname>Brannan</surname><given-names>S.K.</given-names></name><name><surname>Mahurin</surname><given-names>R.K.</given-names></name><name><surname>Jerabek</surname><given-names>P.A.</given-names></name><name><surname>Brickman</surname><given-names>J.S.</given-names></name><name><surname>Tekell</surname><given-names>J.L.</given-names></name><name><surname>Silva</surname><given-names>J.A.</given-names></name><name><surname>McGinnis</surname><given-names>S.</given-names></name><name><surname>Glass</surname><given-names>T.G.</given-names></name><name><surname>Martin</surname><given-names>C.C.</given-names></name><etal/></person-group><article-title>Cingulate function in depression: A potential predictor of treatment response</article-title><source>Neuroreport</source><year>1997</year><volume>8</volume><fpage>1057</fpage><lpage>1061</lpage><pub-id pub-id-type="doi">10.1097/00001756-199703030-00048</pub-id><?supplied-pmid 9141092?><pub-id pub-id-type="pmid">9141092</pub-id></element-citation></ref><ref id="B106-ijms-18-02406"><label>106.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kennedy</surname><given-names>S.H.</given-names></name><name><surname>Evans</surname><given-names>K.R.</given-names></name><name><surname>Kruger</surname><given-names>S.</given-names></name><name><surname>Mayberg</surname><given-names>H.S.</given-names></name><name><surname>Meyer</surname><given-names>J.H.</given-names></name><name><surname>McCann</surname><given-names>S.</given-names></name><name><surname>Arifuzzman</surname><given-names>A.I.</given-names></name><name><surname>Houle</surname><given-names>S.</given-names></name><name><surname>Vaccarino</surname><given-names>F.J.</given-names></name></person-group><article-title>Changes in regional brain glucose metabolism measured with positron emission tomography after paroxetine treatment of major depression</article-title><source>Am. J. Psychiatry</source><year>2001</year><volume>158</volume><fpage>899</fpage><lpage>905</lpage><pub-id pub-id-type="doi">10.1176/appi.ajp.158.6.899</pub-id><?supplied-pmid 11384897?><pub-id pub-id-type="pmid">11384897</pub-id></element-citation></ref><ref id="B107-ijms-18-02406"><label>107.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lisiecka</surname><given-names>D.</given-names></name><name><surname>Meisenzahl</surname><given-names>E.</given-names></name><name><surname>Scheuerecker</surname><given-names>J.</given-names></name><name><surname>Schoepf</surname><given-names>V.</given-names></name><name><surname>Whitty</surname><given-names>P.</given-names></name><name><surname>Chaney</surname><given-names>A.</given-names></name><name><surname>Moeller</surname><given-names>H.-J.</given-names></name><name><surname>Wiesmann</surname><given-names>M.</given-names></name><name><surname>Frodl</surname><given-names>T.</given-names></name></person-group><article-title>Neural correlates of treatment outcome in major depression</article-title><source>Int. J. Neuropsychopharmacol.</source><year>2011</year><volume>14</volume><fpage>521</fpage><lpage>534</lpage><pub-id pub-id-type="doi">10.1017/S1461145710001513</pub-id><?supplied-pmid 21205435?><pub-id pub-id-type="pmid">21205435</pub-id></element-citation></ref><ref id="B108-ijms-18-02406"><label>108.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Williams</surname><given-names>L.M.</given-names></name><name><surname>Korgaonkar</surname><given-names>M.S.</given-names></name><name><surname>Song</surname><given-names>Y.C.</given-names></name><name><surname>Paton</surname><given-names>R.</given-names></name><name><surname>Eagles</surname><given-names>S.</given-names></name><name><surname>Goldstein-Piekarski</surname><given-names>A.</given-names></name><name><surname>Grieve</surname><given-names>S.M.</given-names></name><name><surname>Harris</surname><given-names>A.W.</given-names></name><name><surname>Usherwood</surname><given-names>T.</given-names></name><name><surname>Etkin</surname><given-names>A.</given-names></name></person-group><article-title>Amygdala reactivity to emotional faces in the prediction of general and medication-specific responses to antidepressant treatment in the randomized iSPOT-D trial</article-title><source>Neuropsychopharmacology</source><year>2015</year><volume>40</volume><fpage>2398</fpage><pub-id pub-id-type="doi">10.1038/npp.2015.89</pub-id><?supplied-pmid 25824424?><pub-id pub-id-type="pmid">25824424</pub-id></element-citation></ref><ref id="B109-ijms-18-02406"><label>109.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Uher</surname><given-names>R.</given-names></name><name><surname>Tansey</surname><given-names>K.E.</given-names></name><name><surname>Dew</surname><given-names>T.</given-names></name><name><surname>Maier</surname><given-names>W.</given-names></name><name><surname>Mors</surname><given-names>O.</given-names></name><name><surname>Hauser</surname><given-names>J.</given-names></name><name><surname>Dernovsek</surname><given-names>M.Z.</given-names></name><name><surname>Henigsberg</surname><given-names>N.</given-names></name><name><surname>Souery</surname><given-names>D.</given-names></name><name><surname>Farmer</surname><given-names>A.</given-names></name></person-group><article-title>An inflammatory biomarker as a differential predictor of outcome of depression treatment with escitalopram and nortriptyline</article-title><source>Am. J. Psychiatry</source><year>2014</year><volume>171</volume><fpage>1278</fpage><lpage>1286</lpage><pub-id pub-id-type="doi">10.1176/appi.ajp.2014.14010094</pub-id><?supplied-pmid 25017001?><pub-id pub-id-type="pmid">25017001</pub-id></element-citation></ref><ref id="B110-ijms-18-02406"><label>110.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Benes</surname><given-names>F.M.</given-names></name><name><surname>Matzilevich</surname><given-names>D.</given-names></name><name><surname>Burke</surname><given-names>R.E.</given-names></name><name><surname>Walsh</surname><given-names>J.</given-names></name></person-group><article-title>The expression of proapoptosis genes is increased in bipolar disorder, but not in schizophrenia</article-title><source>Mol. Psychiatry</source><year>2006</year><volume>11</volume><fpage>241</fpage><lpage>251</lpage><pub-id pub-id-type="doi">10.1038/sj.mp.4001758</pub-id><?supplied-pmid 16288314?><pub-id pub-id-type="pmid">16288314</pub-id></element-citation></ref><ref id="B111-ijms-18-02406"><label>111.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Andreazza</surname><given-names>A.C.</given-names></name><name><surname>Kauer-Sant&#x02019;anna</surname><given-names>M.</given-names></name><name><surname>Frey</surname><given-names>B.N.</given-names></name><name><surname>Bond</surname><given-names>D.J.</given-names></name><name><surname>Kapczinski</surname><given-names>F.</given-names></name><name><surname>Young</surname><given-names>L.T.</given-names></name><name><surname>Yatham</surname><given-names>L.N.</given-names></name></person-group><article-title>Oxidative stress markers in bipolar disorder: A meta-analysis</article-title><source>J. Affect. Disord.</source><year>2008</year><volume>111</volume><fpage>135</fpage><lpage>144</lpage><pub-id pub-id-type="doi">10.1016/j.jad.2008.04.013</pub-id><?supplied-pmid 18539338?><pub-id pub-id-type="pmid">18539338</pub-id></element-citation></ref><ref id="B112-ijms-18-02406"><label>112.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Murray</surname><given-names>J.</given-names></name><name><surname>Taylor</surname><given-names>S.W.</given-names></name><name><surname>Zhang</surname><given-names>B.</given-names></name><name><surname>Ghosh</surname><given-names>S.S.</given-names></name><name><surname>Capaldi</surname><given-names>R.A.</given-names></name></person-group><article-title>Oxidative damage to mitochondrial complex I due to peroxynitrite: Identification of reactive tyrosines by mass spectrometry</article-title><source>J. Biol. Chem.</source><year>2003</year><volume>278</volume><fpage>37223</fpage><lpage>37230</lpage><pub-id pub-id-type="doi">10.1074/jbc.M305694200</pub-id><?supplied-pmid 12857734?><pub-id pub-id-type="pmid">12857734</pub-id></element-citation></ref></ref-list></back><floats-group><fig id="ijms-18-02406-f001" orientation="portrait" position="float"><label>Figure 1</label><caption><p>Treatment of major depressive episodes and the longitudinal stabilization of mood disorder. (Abbreviations: AD, antidepressant; AAP, atypical antipsychotics; MS, mood stabilizer).</p></caption><graphic xlink:href="ijms-18-02406-g001"/></fig><table-wrap id="ijms-18-02406-t001" orientation="portrait" position="float"><object-id pub-id-type="pii">ijms-18-02406-t001_Table 1</object-id><label>Table 1</label><caption><p>Randomized controlled trials of antidepressant use in acute phase in bipolar depression.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Study</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Number of Bipolar Subjects (Type)</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Duration (Weeks)</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Antidepressant vs. Comparators (Doses, mg/d)</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Primary Outcome Evaluation</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Efficacy of Responders/Cases</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Mood Switching</th></tr></thead><tbody><tr><td colspan="7" align="center" valign="middle" style="border-bottom:solid thin" rowspan="1">TCAs</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Bochetta et al., 1993 [<xref rid="B38-ijms-18-02406" ref-type="bibr">38</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">30 (BP I &#x00026; II)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">4</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Amitriptyline 55 &#x000b1; 10 vs. <sc>l</sc>-sulpiride 62 &#x000b1; 13; add-on lithium</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Response rate (&#x02265;50% reduction from baseline HAMD)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Amitriptyline 86% vs. <sc>l</sc>-sulpiride 93%; no significant differences</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Only <sc>l</sc>-sulpiride 1 patients</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Agosti and Steward, 2007 [<xref rid="B39-ijms-18-02406" ref-type="bibr">39</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">70 (BP II)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">6</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Imipramine 50&#x02013;300 vs. Phenelzine 15&#x02013;90 vs. Placebo</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Responders (CGI-I 1 or 2)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Imipramine 56.5% vs. Phenelzine 52% vs. Placebo 22.7%; no comparison within BP, only BP vs. UP comparison</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">None</td></tr><tr><td colspan="7" align="center" valign="middle" style="border-bottom:solid thin" rowspan="1">MAO inhibitors vs. TCAs</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Himmelhoch et al., 1991 [<xref rid="B40-ijms-18-02406" ref-type="bibr">40</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">56 (BP I &#x00026; II)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">6</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Tranylcypromine 20&#x02013;60 vs. Imipramine 100&#x02013;300</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">CGI score of +2 or +3 for at least 2 weeks</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Tranylcypromine 81% vs. Imipramine 48%; Tranylcypromine &#x0003e; imipramine</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Tranylcypromine 12% vs. Imipramine 24%</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Thase et al., 1992 [<xref rid="B41-ijms-18-02406" ref-type="bibr">41</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">16 (BP I &#x00026; II)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">6</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Tranylcypromine &#x0003e;30 vs. Imipramine &#x0003e;150; Crossover study, vice versa in those non-responding in the initial study(101)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Unclear (BDI; HAM-D; Pittsburgh reversed vegetative symptom scale)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">75% for Imipramine to Tranylcypromine vs. 25% for Tranylcypromine to Imipramine; no mention of significance</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1/4 patients in imipramine (25%)</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Silverstone, 2001 [<xref rid="B42-ijms-18-02406" ref-type="bibr">42</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">156 (BP I &#x00026; II)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">8</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Moclobemide 450&#x02013;750 vs. Imipramine 150&#x02013;250</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Change from baseline HAMD</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Moclobemide 9.9% vs. Imipramine 13.0%; no significant difference</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Moclobemide 3.7% vs. Imipramine 11%</td></tr><tr><td colspan="7" align="center" valign="middle" style="border-bottom:solid thin" rowspan="1">SSRIs vs. placebo</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Cohn et al., 1989 [<xref rid="B43-ijms-18-02406" ref-type="bibr">43</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">89 (BP I &#x00026; II)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">6</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Fluoxetine 20 to 80 vs. Imipramine 75 to 300 vs. Placebo</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Response rate (&#x0003e;50% reduction from baseline HAMD)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Fluoxetine 86% vs. Imipraime 57% vs. Placebo 38%; Fluoxetine &#x0003e; placebo, fluoxetine &#x0003e; imipramine</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Fluoxetine 0% vs. Imipramine 6.7% vs. Placebo 3.4%</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Nemeroff et al., 2001 [<xref rid="B44-ijms-18-02406" ref-type="bibr">44</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">117 (BP I &#x00026; II)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">10</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Paroxetine 20&#x02013;50 vs. Imipramine 50&#x02013;300 vs. Placebo; add-on lithium</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Change from baseline HAMD and CGI-I</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Paroxetine 45.5% vs. Imipramine 38.9% vs. Placebo 34.9%; no significant difference</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Paroxetine 0% vs. Imipramine 7.7% vs. Placebo: 2.3%</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Tohen et al., 2003 [<xref rid="B34-ijms-18-02406" ref-type="bibr">34</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">833 (BP I)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">8</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Fluoxetine 25&#x02013;50 vs. OFC (olanzapine 6&#x02013;12) vs. Placebo</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Change from baseline MADRS</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">OFC &#x02212;18.5 vs. Olanzapine &#x02212;15.0 vs. Placebo &#x02212;11.9; OFC &#x0003e; placebo, OFC &#x0003e; olanzapine</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">OFC 6.4% vs. Olanzapine 5.7% vs. Placebo 6.7% ;no significant difference</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Sachs et al., 2007 [<xref rid="B36-ijms-18-02406" ref-type="bibr">36</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">366 (BP I &#x00026; II)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">26</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Paroxetine 20&#x02013;40 vs. bupropion 150&#x02013;300 vs. Placebo; add-on mood stabilizers</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Durable recovery : At least eight consecutive weeks of euthymia</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Antidepressants 23% vs. Placebo 27.3%; no significant difference</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Antidepressants 10.1% vs. Placebo 10.7%</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">McElroy et al., 2010 [<xref rid="B31-ijms-18-02406" ref-type="bibr">31</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">740 (BP I &#x00026; II)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">8</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Paroxetine 20 vs. Quetiapine 300 or 600 vs. Placebo</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Change from baseline MADRS</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Paroxetine &#x02212;13.76 vs. Quetiapine 300, &#x02212;16.19 vs. Quetiapine 600, &#x02212;16.31 vs. Placebo &#x02212;12.60; both quetiapine &#x0003e; placebo, paroxetine &#x0003e; placebo</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Paroxetine 10.7% vs. Quetiapine 300, 2.1% vs. Quetiapine 600, 4.1% vs. Placebo 8.9%</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Altshuler et al., 2017 [<xref rid="B45-ijms-18-02406" ref-type="bibr">45</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">142 (BP II)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">16</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Sertraline &#x0003e;100 vs. Lithium &#x0003e;900 vs. Combination of both drugs</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Switch to hypomania or mania</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Sertraline 73.3% vs. Lithium 67.4% vs. Combination of both drugs 47.9%; no significant difference</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Sertraline 17.8% vs. Lithium 14.3% vs. Combination of both drugs 10.4%; no significant difference</td></tr><tr><td colspan="7" align="center" valign="middle" style="border-bottom:solid thin" rowspan="1">SSRIs vs. other drugs</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Young et al., 2000 [<xref rid="B46-ijms-18-02406" ref-type="bibr">46</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">27 (BP I &#x00026; II)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">6</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Paroxetine 36 (mean) vs. Lithium 1300 (mean) or Divalproex 1200 (mean); add-on lithium or divalproex</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Change from baseline HAMD, YMRS, and GAF</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">For HAMD, paroxetine + lithium or divalproex &#x0003e; lithium or divalproex; for YMRS, no difference; for GAF, paroxetine+lithium or divalproex &#x0003e; lithium or divalproex</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Paroxetine was not associated with the emergence of manic symptoms</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Vieta et al., 2002 [<xref rid="B47-ijms-18-02406" ref-type="bibr">47</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">60 (BP I &#x00026; II)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">6</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Paroxetine: 20&#x02013;60 vs. Venlafaxine: 75&#x02013;450</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Change from baseline HAMD</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Paroxetine: 43% vs. Venlafaxine: 48%; venlafaxine &#x0003e; paroxetine</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Paroxetine 3% vs. Venlafaxine 13%</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Shelton et al., 2004 [<xref rid="B48-ijms-18-02406" ref-type="bibr">48</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">30 (BP I &#x00026; II)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">12</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Paroxetine 35.0 &#x000b1; 21.2 vs., Risperidone 2.15 &#x000b1; 1.2 vs. Combination of both drugs; add-on mood stabilizers</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Change from baseline HAMD</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Paroxetine 5.6 &#x000b1; 6.5vs, Risperidone 5.2 &#x000b1; 8.7vs. Combination of both drugs 6.3 &#x000b1; 6.5; no significant difference</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">None</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Post et al., 2006 [<xref rid="B49-ijms-18-02406" ref-type="bibr">49</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">184 (BP I &#x00026; II)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">10</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Sertraline 50&#x02013;200 vs. Bupropion 75&#x02013;450 vs. Venlafaxine 37.5&#x02013;375; add-on mood stabilizers</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Response ( &#x02265;50% improvement in IDS score or a decrease in the CGI-BP depression score of &#x02265; 2)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Bupropion 49% vs. Sertraline 53% vs. Venlafaxine 51%; no significant difference</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Bupropion 14%, Sertraline 16% Venlafaxine 31%; venlafaxine &#x0003e; bupropion or sertraline</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Schaffer et al., 2006 [<xref rid="B50-ijms-18-02406" ref-type="bibr">50</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">20 (BP I &#x00026; II)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">12</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Ciralopram 10&#x02013;30 vs. Lamotrigine 50&#x02013;200 (no divalproex) and 25&#x02013;100 (with divalproex); add-on mood stabilizers</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Change from baseline MADRS</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Ciralopram &#x02212;14.2 vs. Lamotrigine &#x02212;13.3; no significant difference</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Ciralopram 1 patient vs. Lamotrigine 1 patients; no significant difference</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Brown et al., 2006 [<xref rid="B35-ijms-18-02406" ref-type="bibr">35</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">410 (BP I)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">7</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Fluoxetine (OFC) 25&#x02013;50 vs. Lamotrigine 200</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Change from baseline CGI-S</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Fluoxetine (OFC) &#x02212;1.43 vs. Lamotrigine &#x02212;1.18; OFC &#x0003e; lamotrigine</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Fluoxetine (OFC) 4.0% vs. Lamotrigine 5.2%; no significant difference</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Altshuler et al., 2017 [<xref rid="B45-ijms-18-02406" ref-type="bibr">45</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">142 (BP II)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">16</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Sertraline &#x0003e;100 vs. Lithium &#x0003e;900 vs. Combination of both drugs</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Switch to hypomania or mania</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Sertraline 73.3% vs. Lithium 67.4% vs. Combination of both drugs 47.9%; no significant difference</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Sertraline 17.8% vs. Lithium 14.3% vs. Combination of both drugs 10.4%; no significant difference</td></tr><tr><td colspan="7" align="center" valign="middle" style="border-bottom:solid thin" rowspan="1">SNRIs</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Amsterdam, 1998 [<xref rid="B51-ijms-18-02406" ref-type="bibr">51</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">17 (BP II)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">6</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Venlafaxine 37.5&#x02013;225</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Change from baseline HAMD</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Venlafaxine 10 &#x000b1; 8; no comparison within BP, only BP vs. UP comparison</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">None</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Amsterdam, 2000 [<xref rid="B52-ijms-18-02406" ref-type="bibr">52</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">15 (BP II)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">6</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Venlafaxine 37.5&#x02013;225</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Response rate (&#x02265;50% reduction from baseline HAMD)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Venlafaxine 63%; no comparison within BP, only BP vs. UP comparison</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">None</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Amsterdam, 2016 [<xref rid="B53-ijms-18-02406" ref-type="bibr">53</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">129 (BP II)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">12</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Venlafaxine 37.5&#x02013;75 vs. Lithium 300&#x02013;600mg</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Response rate (&#x0003e;50% reduction from baseline HAMD plus final CGI-S)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Venlafaxine 67.7% vs. Lithium 34.4%; venlafaxine &#x0003e; lithium</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">None</td></tr><tr><td colspan="7" align="center" valign="middle" style="border-bottom:solid thin" rowspan="1">NDRIs</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Sachs et al., 1994 [<xref rid="B54-ijms-18-02406" ref-type="bibr">54</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">15 (BP I &#x00026; II)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">8</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Bupropion 358 &#x000b1; 62 vs. Desipramine 140 &#x000b1; 46</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Response rate (&#x0003e;50% reduction from baseline HAMD)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Bupropion 63% vs. Desipramine 71%; no significant difference</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Bupropion 11% vs. Desipramine 50%; Desipramine &#x0003e; bupropion</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Grossman et al., 1999 [<xref rid="B55-ijms-18-02406" ref-type="bibr">55</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">16 (BP I)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">6</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Bupropion 450 vs. Idazoxan 240; add-on lithium</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Change from baseline HAMD</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Bupropion &#x02212;1.54 vs. Idazoxan &#x02212;1.06; no significant difference</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">No mention</td></tr><tr><td colspan="7" align="center" valign="middle" style="border-bottom:solid thin" rowspan="1">Agomelatine</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Yatham et al., 2016 [<xref rid="B37-ijms-18-02406" ref-type="bibr">37</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">344 (BP I)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">8</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Agomelatine 25&#x02013;50 vs. Placebo; add on lithium or valproate</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Change from baseline MADRS</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Agomelatine &#x02212;15.4 vs. Placebo &#x02212;15.2; no significant difference</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Agomelatine 4.1% vs. Placebo 3.5%</td></tr></tbody></table><table-wrap-foot><fn><p>(Abbreviations: BDI, Beck Depression Inventory; HAMD, ; CGI-I, clinical global impression severity-improvement; MADRS, Montgomery-Asberg depression rating scale; OFC olanzapine-fluoxetine combination; IDS, Inventory of depressive symptomatology; CGI-BP, clinical global impression-bipolar version, YMRS, young mania rating scale; GAF, global assessment of functioning scale).</p></fn></table-wrap-foot></table-wrap></floats-group></article>